Entinostat (MS-275)

Name: Entinostat (MS-275)
Brand: Selleck Chemicals
SKU: S1053
Rating: 5 (324 reviews)

For research use only.

Catalog No.S1053 Synonyms: SNDX-275

324 publications

CAS No. 209783-80-2

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.

Selleck's Entinostat (MS-275) has been cited by 324 publications

Science, 2021, 372(6537)eaba1786

PubMed: 33795428 ( click the link to review the publication )

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Nat Genet, 2020, 10.1038/s41588-020-00729-3

PubMed: 33139953 ( click the link to review the publication )

Cell, 2019, 178(5):1115-1131

PubMed: 31442404 ( click the link to review the publication )

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Immunol, 2014, 15(5):439-48

PubMed: 24681565 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Nat Chem Biol, 2021, 10.1038/s41589-021-00772-z

PubMed: 33723432 ( click the link to review the publication )

Nat Commun, 2021, 12(1):2699

PubMed: 33976188 ( click the link to review the publication )

Neuro Oncol, 2021, 23(3):376-386

PubMed: 33130903 ( click the link to review the publication )

Clin Cancer Res, 2021, 10.1158/1078-0432.CCR-20-2357

PubMed: 33994371 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:641987

PubMed: 34041236 ( click the link to review the publication )

Mol Neurobiol, 2021, 10.1007/s12035-021-02361-6

PubMed: 33772465 ( click the link to review the publication )

Gynecol Oncol, 2021, S0090-8258(21)00325-5

PubMed: 33867143 ( click the link to review the publication )

J Virol, 2021, JVI0085321

PubMed: 34232065 ( click the link to review the publication )

J Enzyme Inhib Med Chem, 2021, 36(1):34-47

PubMed: 33100043 ( click the link to review the publication )

Genes (Basel), 2021, 12(2)260

PubMed: 33670166 ( click the link to review the publication )

Sci China Life Sci, 2021, 10.1007/s11427-020-1855-4

PubMed: 33420926 ( click the link to review the publication )

Cold Spring Harb Mol Case Stud, 2021, mcs.a006049

PubMed: 33722797 ( click the link to review the publication )

Sci Adv, 2021, 7(9)eabe3348

PubMed: 33637530 ( click the link to review the publication )
Life Sci, 2021, 271:119127

PubMed: 33515561 ( click the link to review the publication )

Nat Protoc, 2020, 15(3):1209-1236

PubMed: 32051612 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(11):e12525

PubMed: 33026191 ( click the link to review the publication )

EMBO Rep, 2020, 4;21(3):e49254

PubMed: 32009295 ( click the link to review the publication )

EMBO Rep, 2020, 21:e50162

PubMed: 32314873 ( click the link to review the publication )

Theranostics, 2020, 10(21):9644-9662

PubMed: 32863951 ( click the link to review the publication )

Elife, 2020, 9e59780

PubMed: 33074102 ( click the link to review the publication )

J Autoimmun, 2020, 108:102379

PubMed: 31883829 ( click the link to review the publication )

J Crohns Colitis, 2020, 14(8):1103-1118

PubMed: 32030401 ( click the link to review the publication )

Cells, 2020, 21;9(5):E1280

PubMed: 32455774 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0336

PubMed: 32978226 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0756

PubMed: 33334730 ( click the link to review the publication )

Mol Cancer Ther, 2020, molcanther.1160.2019

PubMed: 33323457 ( click the link to review the publication )

J Mol Cell Cardiol, 2020, 149:73-81

PubMed: 32971072 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:573820

PubMed: 33195208 ( click the link to review the publication )

Cell Biol Toxicol, 2020, 10.1007/s10565-020-09560-2

PubMed: 33040242 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

J Transl Med, 2020, 7;18(1):159

PubMed: 32264925 ( click the link to review the publication )

Cell Signal, 2020, 70:109573

PubMed: 32087304 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(2):343-356

PubMed: 31932908 ( click the link to review the publication )

PLoS One, 2020, 15;15(5):e0232985

PubMed: 32413049 ( click the link to review the publication )

Theranostics, 2020, 10(16):7351-7368

PubMed: 32641996 ( click the link to review the publication )

Oncol Lett, 2020, 19(1):460-468

PubMed: 31897159 ( click the link to review the publication )

Sci Adv, 2020, 6(29):eaba1941

PubMed: 32832623 ( click the link to review the publication )
Pathol Res Pract, 2020, 216(4):152867

PubMed: 32067803 ( click the link to review the publication )

Neoplasia, 2020, 22(9):376-389

PubMed: 32629178 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(14):14174-14188

PubMed: 32692721 ( click the link to review the publication )

JCI Insight, 2020, 5(4)

PubMed: 32102981 ( click the link to review the publication )

Eur J Immunol, 2020, 10.1002/eji.202048566

PubMed: 32644192 ( click the link to review the publication )

Mol Psychiatry, 2020, 10.1038/s41380-020-00958-2

PubMed: 33235333 ( click the link to review the publication )

PLoS Biol, 2020, 18(11):e3000981

PubMed: 33253182 ( click the link to review the publication )

Gastroenterology, 2019, 156(1):187-202

PubMed: 30267710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4192

PubMed: 31519896 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5324

PubMed: 31757943 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz1136

PubMed: 31799598 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(5):1005-1025

PubMed: 30599067 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31561534 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)E645

PubMed: 31083396 ( click the link to review the publication )

Br J Cancer, 2019, 121(12):1039-1049

PubMed: 31690832 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Front Immunol, 2019, 10:409

PubMed: 30915074 ( click the link to review the publication )
Mol Oncol, 2019, 10.1002/1878-0261.12607

PubMed: 31782885 ( click the link to review the publication )

J Mol Med (Berl), 2019, 97(7):957-972

PubMed: 31025088 ( click the link to review the publication )

J Immunol, 2019, 203(12):3199-3208

PubMed: 31732526 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786

PubMed: 31694931 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31380285 ( click the link to review the publication )

Arthritis Res Ther, 2019, 21(1):50

PubMed: 30728075 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(12)

PubMed: 31234549 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Stem Cells Int, 2019, 2019:8451282

PubMed: 30992706 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2019, 22(4):317-328

PubMed: 30668714 ( click the link to review the publication )

Endocrinology, 2019, 160(11):2600-2617

PubMed: 31322702 ( click the link to review the publication )

Skelet Muscle, 2019, 9(1):12

PubMed: 31113472 ( click the link to review the publication )

Biomed Pharmacother, 2019, 115:108570

PubMed: 31054509 ( click the link to review the publication )

Life Sci, 2019, 10.1016/j.lfs.2019.116583

PubMed: 31226417 ( click the link to review the publication )

Cancer Biol Ther, 2019, 20(5):700-710

PubMed: 30571927 ( click the link to review the publication )

J Mol Endocrinol, 2019, 62(2):67-78

PubMed: 30481159 ( click the link to review the publication )

Dev Biol, 2019, 449(2):122-131

PubMed: 30826398 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):669-682

PubMed: 30849634 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

PLoS One, 2019, 14(3):e0213186

PubMed: 30830950 ( click the link to review the publication )

Pain Res Manag, 2019, 2019:1648919

PubMed: 30809320 ( click the link to review the publication )

Oncotarget, 2019, 10(20):1903-1917

PubMed: 30956773 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 10.1016/j.jcmgh.2019.10.005

PubMed: 31654770 ( click the link to review the publication )
eNeuro, 2019, 6(1)

PubMed: 30783618 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):387-401

PubMed: 29200404 ( click the link to review the publication )

Nat Commun, 2018, 9(1):764

PubMed: 29472538 ( click the link to review the publication )

EMBO Rep, 2018, 19(9)

PubMed: 30021835 ( click the link to review the publication )

Cancer Res, 2018, 78(20):5731-5740

PubMed: 30135193 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

Neuropsychopharmacology, 2018, 43(8):1779-1788

PubMed: 29760409 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):623

PubMed: 29795376 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1081

PubMed: 30349042 ( click the link to review the publication )

Arch Toxicol, 2018, 92(7):2227-2243

PubMed: 29845424 ( click the link to review the publication )

Basic Res Cardiol, 2018, 114(1):3

PubMed: 30446837 ( click the link to review the publication )

Oncoimmunology, 2018, 7(11):e1466018

PubMed: 30377559 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2013-2023

PubMed: 29934340 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2018, 1864(8):2610-2622

PubMed: 29684588 ( click the link to review the publication )

Oncogenesis, 2018, 7(4):36

PubMed: 29691367 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(11)

PubMed: 30424007 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(8)

PubMed: 30081552 ( click the link to review the publication )

Sci Rep, 2018, 8(1):8492

PubMed: 29855565 ( click the link to review the publication )

Sci Rep, 2018, 8(1):12886

PubMed: 30150730 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13638

PubMed: 30206377 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9391

PubMed: 29925922 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )
Sci Rep, 2018, 8(1):12886

PubMed: 30150730 ( click the link to review the publication )

Mol Pharmacol, 2018, 94(2):793-801

PubMed: 29880639 ( click the link to review the publication )

Biochem J, 2018, 475(24):3921-3932

PubMed: 30552170 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

Alcohol Clin Exp Res, 2018, 42(11):2160-2171

PubMed: 30103280 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(1):65-75

PubMed: 29721849 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207915

PubMed: 30481203 ( click the link to review the publication )

PLoS One, 2018, 13(3):e0194661

PubMed: 29579087 ( click the link to review the publication )

J Med Virol, 2018, 90(9):1478-1485

PubMed: 29704439 ( click the link to review the publication )

Med Sci Monit, 2018, 24:2620-2630

PubMed: 29704392 ( click the link to review the publication )

Oncol Lett, 2018, 16(2):1967-1974

PubMed: 30008890 ( click the link to review the publication )

JCI Insight, 2018, 3(4)

PubMed: 29467324 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36413-36429

PubMed: 30559927 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )

Oncotarget, 2018, 9(39):25630-25646

PubMed: 29876013 ( click the link to review the publication )

Cond Med, 2018, 1(2):64-72

PubMed: 30135960 ( click the link to review the publication )

Oncotarget, 2018, 9(28):19597-19612

PubMed: 29731968 ( click the link to review the publication )

Oncotarget, 2018, 9(63):32182-32190

PubMed: 30181808 ( click the link to review the publication )

Data Brief, 2018, 17:1314-1319

PubMed: 29876485 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(11)E3539

PubMed: 30424007 ( click the link to review the publication )

Korean J Physiol Pharmacol, 2018, 22(1):23-33

PubMed: 29302209 ( click the link to review the publication )

JCI Insight, 2018, 3(22)125568

PubMed: 30429379 ( click the link to review the publication )

J Clin Invest, 2017, 127(6):2235-2248

PubMed: 28436940 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(11):6334-6349

PubMed: 28369619 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2017, 114(51):E10981-E10990

PubMed: 29203668 ( click the link to review the publication )

Cell Rep, 2017, 19(4):875-889

PubMed: 28445736 ( click the link to review the publication )

Elife, 2017, 6e22767

PubMed: 28318487 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(21):3865-3880

PubMed: 28832971 ( click the link to review the publication )

J Med Chem, 2017, 60(13):5334-5348

PubMed: 28581289 ( click the link to review the publication )

Plant Physiol, 2017, 175(4):1760-1773

PubMed: 29018096 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Cell Chem Biol, 2017, 24(7):858-869

PubMed: 28669525 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Discov, 2017, 7(8):852-867

PubMed: 28408401 ( click the link to review the publication )

Front Immunol, 2017, 8:671

PubMed: 28659914 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(12):2689-2700

PubMed: 28802253 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2017, 6:54-65

PubMed: 28664166 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

J Virol, 2017, 91(16)

PubMed: 28566376 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10921

PubMed: 28883618 ( click the link to review the publication )

Sci Rep, 2017, 7(1):12084

PubMed: 28935977 ( click the link to review the publication )

Sci Rep, 2017, 7(1):8641

PubMed: 28819194 ( click the link to review the publication )

Mech Ageing Dev, 2017, 166:6-15

PubMed: 28843433 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 361(1):140-150

PubMed: 28174211 ( click the link to review the publication )

J Neuropathol Exp Neurol, 2017, 76(12):1000-1007

PubMed: 29136455 ( click the link to review the publication )

J Endocrinol, 2017, 233(3):369-379

PubMed: 28438776 ( click the link to review the publication )
Am J Physiol Renal Physiol, 2017, 312(3):F502-F515

PubMed: 28052874 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

Int J Mol Med, 2017, 40(3):661-672

PubMed: 28677722 ( click the link to review the publication )

Bioorg Med Chem, 2017, 25(7):2105-2132

PubMed: 28259528 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186620

PubMed: 29045501 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:61-69

PubMed: 28315487 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:3-10

PubMed: 27761809 ( click the link to review the publication )

Oncotarget, 2017, 8(69):114156-114172

PubMed: 29371976 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93825-93838

PubMed: 29212192 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3172-3187

PubMed: 29423038 ( click the link to review the publication )

Oncotarget, 2017, 8(47):83155-83170

PubMed: 29137331 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4079-4095

PubMed: 27863422 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:375-385

PubMed: 27761836 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29371976 ( click the link to review the publication )

Sci Rep, 2017, 589:97-106

PubMed: 28273598 ( click the link to review the publication )

Nat Microbiol, 2016, 1:16174

PubMed: 27694949 ( click the link to review the publication )

Kidney Int, 2016, 89(2):317-26

PubMed: 26509586 ( click the link to review the publication )

Cancer Res, 2016, 76(10):3067-77

PubMed: 26980768 ( click the link to review the publication )

Cell Death Differ, 2016, 23(8):1312-21

PubMed: 26915294 ( click the link to review the publication )

Sci Signal, 2016, 9(422):ra34

PubMed: 27048565 ( click the link to review the publication )
J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:76

PubMed: 27437033 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:62

PubMed: 27231489 ( click the link to review the publication )

Oncoimmunology, 2016, 5(11):e1219008

PubMed: 27999738 ( click the link to review the publication )

Oncoimmunology, 2016, 5(6):e1164919

PubMed: 27471639 ( click the link to review the publication )

Osteoarthritis Cartilage, 2016, 24(8):1451-60

PubMed: 27072078 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(2):299-312

PubMed: 26772204 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2432-2441

PubMed: 27474150 ( click the link to review the publication )

Pharmacol Res, 2016, 103:328-39

PubMed: 26657418 ( click the link to review the publication )

Transl Psychiatry, 2016, 6(12):e974

PubMed: 27922638 ( click the link to review the publication )

Dis Model Mech, 2016, 9(5):541-52

PubMed: 26989193 ( click the link to review the publication )

J Virol, 2016, 90(20):9018-28

PubMed: 27466424 ( click the link to review the publication )

J Cell Mol Med, 2016, 20(12):2289-2298

PubMed: 27420561 ( click the link to review the publication )

Front Cell Neurosci, 2016, 10:221

PubMed: 27729849 ( click the link to review the publication )

Front Cell Neurosci, 2016, 9:510

PubMed: 26793062 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2016, 311(1):L124-34

PubMed: 27233998 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2016, 10.1093/ijnp/pyw035

PubMed: 27207921 ( click the link to review the publication )

Mol Brain, 2016, 9(1):79

PubMed: 27535553 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(5):546-57

PubMed: 27029345 ( click the link to review the publication )

BMC Cancer, 2016, 10.1186/s12885-016-2353-7

PubMed: 27188282 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )

Biol Chem, 2016, 397(1):75-83

PubMed: 26431101 ( click the link to review the publication )
Methods Enzymol, 2016, 573:161-81

PubMed: 27372753 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep28025

PubMed: 27320682 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71696-71702

PubMed: 27765934 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7390-402

PubMed: 26862729 ( click the link to review the publication )

Gene Regul Syst Bio, 2016, 10:9-13

PubMed: 26823649 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6727-47

PubMed: 26734995 ( click the link to review the publication )

Blood, 2015, 5;125(6):941-8

PubMed: 25468569 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms7537

PubMed: ( click the link to review the publication )

Nat Commun, 2015, 6:7023

PubMed: 25960197 ( click the link to review the publication )

Nat Commun, 2015, 6:6537

PubMed: 26055519 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(14):3230-3240

PubMed: 25813020 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Control Release, 2015, 204:20-9

PubMed: 25681050 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 26701908 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Am J Transplant, 2015, 10.1111/ajt.13106

PubMed: 25708614 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: 25490700 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

J Neurosci, 2015, 35(3):1250-9

PubMed: 25609639 ( click the link to review the publication )

Br J Cancer, 2015, 112(2):329-37

PubMed: 25514379 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: 25284154 ( click the link to review the publication )
Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(7):3984-94

PubMed: 25896701 ( click the link to review the publication )

Toxicol Sci, 2015, 148(1):220-8

PubMed: 26251326 ( click the link to review the publication )

Sci Rep, 2015, 5:16873

PubMed: 26585834 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2015, 10.1093/ijnp/pyv029

PubMed: 25762717 ( click the link to review the publication )

Front Neurosci, 2015, 9:319

PubMed: 26441495 ( click the link to review the publication )

Breast Cancer Res Treat, 2015, 151(2):281-94

PubMed: 25904215 ( click the link to review the publication )

Virology, 2015, 485:340-54

PubMed: 26331681 ( click the link to review the publication )

J Appl Physiol (1985), 2015, 119(4):342-51

PubMed: 26112243 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144660

PubMed: 26713848 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0137699

PubMed: 26361334 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Future Virol, 2015, 10(4), 351–356

PubMed: ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(12):1375-85

PubMed: 26297712 ( click the link to review the publication )

Genes Cancer, 2015, 6(5-6):184-213

PubMed: 26124919 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25784-800

PubMed: 26329759 ( click the link to review the publication )

Sheng Li Xue Bao, 2015, 67(5):447-54

PubMed: 26490061 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25801-14

PubMed: 26317649 ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )

Genes Dev, 2014, 28(14):1578-91

PubMed: 25030697 ( click the link to review the publication )

PLoS Biol, 2014, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28924

PubMed: 24771510 ( click the link to review the publication )

Addict Biol, 2014, 10.1111/adb.12161.

PubMed: 25041570 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )
Mol Cancer Res, 2014, 12(1):32-7

PubMed: 24165483 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 7):1441-53

PubMed: 24463822 ( click the link to review the publication )

Eur J Immunol, 2014, 44(8):2478-88

PubMed: 24810486 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(3):415-27

PubMed: 24248598 ( click the link to review the publication )

Retrovirology, 2014, 11:67

PubMed: 25116364 ( click the link to review the publication )

Neuromolecular Med, 2014, 16(4):727-41

PubMed: 25063076 ( click the link to review the publication )

Pharmacological Reports, 2014, 49–55

PubMed: ( click the link to review the publication )

PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106784

PubMed: 25198282 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115401

PubMed: 25521755 ( click the link to review the publication )

Pharmacol Rep, 2014, 66(1):49-55

PubMed: 24905306 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 445(2):320-6

PubMed: 24530917 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(12):4516-28

PubMed: 24980831 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(12):6018-33

PubMed: 23625969 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(28):E2621-8

PubMed: 23788661 ( click the link to review the publication )

Genet Mol Biol, 2013, 36(3):299-307

PubMed: 24130434 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(1):118-27

PubMed: 23091117 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Haematologica, 2013, 98(1):57-64

PubMed: 22801959 ( click the link to review the publication )
Int J Cancer, 2013, 132(9):2076-86

PubMed: 23047626 ( click the link to review the publication )

J Neuroscience, 2013, 33(50):19664-76

PubMed: 24336730 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Stem Cells, 2013, 31(7):1434-45

PubMed: 23592435 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(10):2078-87

PubMed: 23939379 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Neurochem, 2013, 129(3):509-15

PubMed: 24147654 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Infect Immun, 2013, 82(2):706-19

PubMed: 24478085 ( click the link to review the publication )

Mol Reprod Dev, 2013, 154(9):1668-79

PubMed: 23693161 ( click the link to review the publication )

Pediatr Nephrol, 2013, 28(10):1909-21

PubMed: 23052657 ( click the link to review the publication )

PLoS One, 2013, 8(9):e74930

PubMed: 24058639 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Exp Hematol, 2013, 41(1):113-23.e2

PubMed: 22989761 ( click the link to review the publication )

Circ Res, 2012, 110(5):739-48

PubMed: 22282194 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(12):2600-9

PubMed: 23012246 ( click the link to review the publication )

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Immunol, 2012, 189(4):1792-9

PubMed: 22786766 ( click the link to review the publication )

Eur Neuropsychopharmacol, 2012, 22(9):651-6

PubMed: 22341945 ( click the link to review the publication )

J Am Heart Assoc, 2012, 1(3):e000901

PubMed: 23130137 ( click the link to review the publication )

J Virol, 2012, 86(6):3073-87

PubMed: 22238308 ( click the link to review the publication )

PLoS One, 2012, 7(7):e41776

PubMed: 22848598 ( click the link to review the publication )
Biochem Biophys Res Commun, 2012, 428(1):121-6

PubMed: 23063976 ( click the link to review the publication )

Biomol Ther (Seoul), 2012, 20(1):81-8

PubMed: 24116279 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

J Thorac Oncol, 2011, 6(7):1152-61

PubMed: 21597390 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2011, 108(49):19629-34

PubMed: 22106282 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 414(1):25-30

PubMed: 21925145 ( click the link to review the publication )

J Biomed Biotechnol, 2011, 2011:371832

PubMed: 21151613 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Mol Pain, 2010, 6:51

PubMed: 20822541 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14335

PubMed: 21179472 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14462

PubMed: 21283510 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Targets

HDAC1 ^[2] (Cell-free assay)	HDAC3 ^[2] (Cell-free assay)
0.51 μM	1.7 μM

In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21^WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. ^[1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. ^[2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
SCC-3	NU\3eHJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXPJR\|UxRTBwME[xJO69VQ>?	NXWweHNURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
ALL-PO	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2fpXGlEPTB;MD6wOlM2PSEQvF2=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
697	NF21bJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NEn4O5lKSzVyPUCuNFk6PzZizszN	NGTk[Xk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H748	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3S1OmlEPTB;MD6xNFM{PCEQvF2=	M{nqXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NKM-1	NY\Te29DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1\vWWlEPTB;MD6xNFkyOiEQvF2=	MlHyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
ES1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NITVNG1KSzVyPUCuNVEzPTVizszN	NHf1XG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H1963	NVTtTm9OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2nBW2lEPTB;MD6xNVU4QSEQvF2=	NYPo[mNYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NCI-H1417	NGmzNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUPjVlJFUUN3ME2wMlEzQTd2IN88US=>	MnfvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NEC8	M2rle2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3jBbWlEPTB;MD6xN\|UzPyEQvF2=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
CRO-AP2	NU[yU45jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{\Ie2lEPTB;MD6xOlg5QSEQvF2=	NYTIT3d3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
A3-KAW	MoG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1T5UGlEPTB;MD6xO\|YzPyEQvF2=	NVTk[lJZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
SF539	NWH5bI5WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1r0[2lEPTB;MD6xPVU6OyEQvF2=	NHzFcIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NOS-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmDtTWM2OD1yLkG5OlE6KM7:TR?=	M{\OeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NTERA-S-cl-D1	M3TOUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWLJR\|UxRTBwMkCxNVMh\|ryP	M4jBdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
COR-L88	NYXCVHJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUTJR\|UxRTBwMkK5OVkh\|ryP	M3L2[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
EM-2	MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFS2cnRKSzVyPUCuNlQxPzlizszN	MknXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
KARPAS-45	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUHJR\|UxRTBwMke4N\|Mh\|ryP	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
DSH1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXXJR\|UxRTBwMki3NFgh\|ryP	M2jSWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
HT-144	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnzoTWM2OD1yLkOwNlU3KM7:TR?=	NGHVbZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
ATN-1	M2XHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MX\JR\|UxRTBwM{C1O\|Yh\|ryP	M4HNfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
HEL	NEjiS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXnJR\|UxRTBwM{GzOFgh\|ryP	NYXHbpBFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NB12	M4OwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHHIOmFKSzVyPUCuN\|E4PTZizszN	NYDkUXVjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
LU-139	NVvTWXJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYHqbVhwUUN3ME2wMlM{PTFizszN	NH;Ge2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
J-RT3-T3-5	Mk\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVrJR\|UxRTBwM{O3NVYh\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
MOLT-13	MmDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{LabmlEPTB;MD6zN\|gyKM7:TR?=	NHyySFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
SR	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NEHPW\|lKSzVyPUCuN\|QzPjFizszN	NVrCc2ZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
CMK	NILDcFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mo\yTWM2OD1yLkO1O\|I4KM7:TR?=	NFz1eIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
ES8	NGLPPZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVTJR\|UxRTBwM{[wNlIh\|ryP	MnPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
LB647-SCLC	MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnjTTWM2OD1yLkO2O\|Mh\|ryP	NETxV\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
TE-8	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1\qbWlEPTB;MD6zOlk{PSEQvF2=	NXL0OnU4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
BV-173	NVjPNYVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkfMTWM2OD1yLkO3NVIyKM7:TR?=	NV\USVhsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
DEL	NWXZWpJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2PneWlEPTB;MD6zO\|Q5PyEQvF2=	M3zPSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
ARH-77	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXnFbJpFUUN3ME2wMlM5OTl\|IN88US=>	NGHEW2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCCIT	M33uSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnjpTWM2OD1yLkO4OlQ6KM7:TR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
RPMI-8402	NVraO4hLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3u2TGlEPTB;MD6zPFcxOSEQvF2=	NWDV[2FPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
MONO-MAC-6	M3rmV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoXPTWM2OD1yLkO4O\|c3KM7:TR?=	MlzPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
SK-MM-2	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NH2yRm9KSzVyPUCuN\|k5PjhizszN	M37xXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
CHP-126	MomwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlmyTWM2OD1yLkSwNlMyKM7:TR?=	NXPIPG17RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
A101D	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3PYTWlEPTB;MD60NFMh\|ryP	NXPlV4hjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
SCH	Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3nxTGlEPTB;MD60NFM1OiEQvF2=	MnHjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NMC-G1	NIrjdYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXzJR\|UxRTBwNECzOlch\|ryP	NHHCcIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H209	MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmXYTWM2OD1yLkSwOlE{KM7:TR?=	NV[2[lFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
MOLT-16	NFXYT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWfJZXhxUUN3ME2wMlQyODF5IN88US=>	NInrPHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
RPMI-6666	MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2r4bGlEPTB;MD60NVEzKM7:TR?=	MnfXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
OPM-2	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NEDHbVFKSzVyPUCuOFE2OTNizszN	NXL1UoVrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
MRK-nu-1	M4LOWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4q2TGlEPTB;MD60N\|E2OyEQvF2=	NF\lU4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
BC-1	NFLDemNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MonrTWM2OD1yLkSzOFA{KM7:TR?=	Mmi0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
MHH-NB-11	NXzySlZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIXyWZZKSzVyPUCuOFM1PTNizszN	M{W5RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
Ramos-2G6-4C10	NX:zWZYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX;SbW5IUUN3ME2wMlQ{QDl5IN88US=>	NYTMS4pqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
LS-513	MnrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFjYZ5RKSzVyPUCuOFQ2ODFizszN	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
K5	Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mkn5TWM2OD1yLkS3NFI2KM7:TR?=	MlflQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
HOP-62	MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlTzTWM2OD1yLkS4N\|U5KM7:TR?=	M4\IfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-H187	NFTGS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlLxTWM2OD1yLkS5NlI4KM7:TR?=	M2\vOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
BE-13	NHvNc2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3LyVmlEPTB;MD60PVY3OSEQvF2=	M3PsVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
HC-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYfJR\|UxRTBwNUC0O\|Mh\|ryP	MkD5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
ACN	MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUXiSG1SUUN3ME2wMlUyODJ6IN88US=>	M{K2PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
HCC1599	NYThT5NPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2nJU2lEPTB;MD61NVU4KM7:TR?=	NYq4[WRlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
MV-4-11	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NX7p[2Z5UUN3ME2wMlU{ODRzIN88US=>	NYf6SpdGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
LC-2-ad	NXj5e2R2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NG[wdZZKSzVyPUCuOVM3PjNizszN	NGizNJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
HL-60	MkfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWX5NXN[UUN3ME2wMlU1OjZzIN88US=>	NWLiS\|lsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NB17	NIG5XHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWTtNndKUUN3ME2wMlU1OzhizszN	NUnqSW1kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
TE-1	M4XWVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGK4T4RKSzVyPUCuOVU{ODZizszN	M1rp[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-H524	M1HUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2PmVGlEPTB;MD61OVQxOSEQvF2=	Mom5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
MZ7-mel	M4TXeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWe5NoNbUUN3ME2wMlU3OTB3IN88US=>	NVvaWlFnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
L-363	NWSxTmRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWTTT\|JYUUN3ME2wMlU3PjV5IN88US=>	NYH2VY5pRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
BL-41	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4njbWlEPTB;MD61Olg5QSEQvF2=	NILxZpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
LU-134-A	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkLpTWM2OD1yLkW3NFc{KM7:TR?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
SIG-M5	NW[0WZpyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1LXZ2lEPTB;MD61O\|g1QCEQvF2=	NI\Nd5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
ONS-76	MkHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4\xNGlEPTB;MD61PFI1OiEQvF2=	NHz6b3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
KARPAS-299	NWfmUYo{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2S5NGlEPTB;MD61PFUxPCEQvF2=	M{TqNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
DU-4475	NUTwcXFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHX3d3ZKSzVyPUCuOVg4ODNizszN	Mn;mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NB69	M1H1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWnSSnVwUUN3ME2wMlU6QDJ3IN88US=>	MkXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
MHH-PREB-1	NGjDSpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{nOXmlEPTB;MD62NFcyQSEQvF2=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
LU-165	NYPucYZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4HhNWlEPTB;MD62NVgyOiEQvF2=	NUDTWIxrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
LOUCY	NWrOendLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4LRe2lEPTB;MD62N\|M3PCEQvF2=	Ml\TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NCI-H526	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVjJR\|UxRTBwNkO1OFEh\|ryP	M3fseFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
KE-37	M1PrRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmTETWM2OD1yLk[0Nlc3KM7:TR?=	NIX3R\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NALM-6	M{DZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3zEVWlEPTB;MD62OFg3KM7:TR?=	NFTkZ3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
CW-2	MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{njSGlEPTB;MD62OVc6PCEQvF2=	NYLlVIpbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
SU-DHL-1	NI\pTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVvJR\|UxRTBwNkW5OFch\|ryP	M3LKUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NB13	NF;ycYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4Pke2lEPTB;MD62OlgyPyEQvF2=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
QIMR-WIL	NVvCUFhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3LNfGlEPTB;MD62PFM1OyEQvF2=	NF\KNIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
ECC12	NWXHXYg4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXrsPIdIUUN3ME2wMlcxODh4IN88US=>	MmTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
KALS-1	M4nlPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFjDdphKSzVyPUCuO\|A1QTJizszN	M2XoSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
COR-L279	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnHGTWM2OD1yLkewPVk3KM7:TR?=	MnO1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NB14	NEjkXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHHtOIFKSzVyPUCuO\|I3OTdizszN	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
CCRF-CEM	NHS2emxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVTJR\|UxRTBwN{S2OlEh\|ryP	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
SW954	NWXpNopvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYfJR\|UxRTBwN{W5PVkh\|ryP	MkTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
IST-SL1	M2PYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIewVZRKSzVyPUCuO\|c{PDhizszN	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
LAMA-84	MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoS4TWM2OD1yLke3OVY4KM7:TR?=	NEPpUVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
Daudi	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYe4eGJqUUN3ME2wMlc4PjhzIN88US=>	M{C5e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
BC-3	NVTDR\|NoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{nxOmlEPTB;MD63PFMxQCEQvF2=	NHOwd4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
HCC2998	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NULmbWNsUUN3ME2wMlc5OzZizszN	NE\lUmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H69	MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXjMOVBSUUN3ME2wMlgxOTR5IN88US=>	M1\acFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
CPC-N	NYO1bIZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MX3JR\|UxRTBwOEC1NlQh\|ryP	NWLCT5dHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NOMO-1	M1y4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Moj6TWM2OD1yLkixNFg1KM7:TR?=	NUDiNo1YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
CESS	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1P5WmlEPTB;MD64NVE6PyEQvF2=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
LC4-1	MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NEXLNGNKSzVyPUCuPFQxODdizszN	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
BL-70	M1jyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHeycG9KSzVyPUCuPFU4ODJizszN	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
ES4	M1TINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1:3TGlEPTB;MD64OVg3QCEQvF2=	MnjlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
HCE-T	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NH\qOYhKSzVyPUCuPFcyPzFizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
JAR	NW[5d\|ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{K0fGlEPTB;MD64O\|gzPyEQvF2=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
ST486	NEXYZZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGK3RVBKSzVyPUCuPFc6OTdizszN	NH7Q[W49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
KS-1	NFvicVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVnJR\|UxRTBwOEiwPVYh\|ryP	M4\P[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
GDM-1	Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml\6TWM2OD1yLki4Olg4KM7:TR?=	NX3iZVJuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
EHEB	NInGSXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnLhTWM2OD1yLkmyOVg2KM7:TR?=	Mof3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
LB2518-MEL	MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUfJR\|UxRTBwOUOyPFQh\|ryP	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
GOTO	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{j2dmlEPTB;MD65OVA4PiEQvF2=	NXuzOGt7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
LXF-289	NHnaZ5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{Pob2lEPTB;MD65OVkxOSEQvF2=	M3PJflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
ES6	NIXZW5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFHGS\|hKSzVyPUCuPVY1OzdizszN	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
OS-RC-2	NIizVWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnH6TWM2OD1yLkm2PFMh\|ryP	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
DMS-153	NV;M[\|ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUfu[lM6UUN3ME2wMlk4PDZ7IN88US=>	NUS5Z4tvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
SK-PN-DW	M3v1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MU\JR\|UxRTBwOUe4N\|Eh\|ryP	NFrkT\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
HH	NU\JelI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NH3Id5hKSzVyPUCuPVg6PTlizszN	MknoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
SH-4	MmD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUnJR\|UxRTFwMEK0NUDPxE1?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
MOLT-4	MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWPJR\|UxRTFwMEO0OVQh\|ryP	M3LDN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
TGW	NXfscHROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmXjTWM2OD1zLkC3Olc2KM7:TR?=	M{ixNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
L-540	NYHzV5F4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX[1OXVjUUN3ME2xMlExPjB2IN88US=>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
PF-382	MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkTHTWM2OD1zLkGxOVE{KM7:TR?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
LC-1F	M{DHPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXXhNGJqUUN3ME2xMlEzODB5IN88US=>	MkLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
OVCAR-4	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3mxfmlEPTB;MT6xN\|E3PSEQvF2=	MkewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
A4-Fuk	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVLJR\|UxRTFwMUWzOlQh\|ryP	NH\XTWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
HCC2218	MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkPBTWM2OD1zLkG2OlQyKM7:TR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
HAL-01	M4\Sbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmnBTWM2OD1zLkG2PVQ{KM7:TR?=	M2rycFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
IST-MEL1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmDFTWM2OD1zLkG3OlU6KM7:TR?=	NGjlcFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H719	NGe5TWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{HFfmlEPTB;MT6xO\|g6QCEQvF2=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
EVSA-T	MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHL0c5ZKSzVyPUGuNVgyOTRizszN	NVjsWGZrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
SK-NEP-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUHTSnBiUUN3ME2xMlIxOjZ4IN88US=>	MnztQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
OCUB-M	NUTsdHVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnfFTWM2OD1zLkKxOFg6KM7:TR?=	M4\JfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
MEG-01	NHjERYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFf2W5pKSzVyPUGuNlIyOThizszN	NI\FNXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
no-10	M2fGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFfjWIZKSzVyPUGuNlMyOTJizszN	NG\neZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
MHH-CALL-2	Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoHjTWM2OD1zLkK0O\|IyKM7:TR?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
SK-N-DZ	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUm3T5BlUUN3ME2xMlI1Pzd4IN88US=>	NInOSpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
SCLC-21H	NYTJWZFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3PteGlEPTB;MT6yOlQ4QCEQvF2=	MonwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
CTV-1	NXqydXVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4P4fGlEPTB;MT6yO\|QzPSEQvF2=	M{HGN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NB1	Ml3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHG3Z5dKSzVyPUGuNlc4OzJizszN	M{OzcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-H64	NHvzUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmjNTWM2OD1zLkK4OFYzKM7:TR?=	NFH1cnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
MDA-MB-134-VI	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYPJR\|UxRTFwMki1O\|ch\|ryP	NVG3TGdkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
LB2241-RCC	MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnizTWM2OD1zLkK4OlY{KM7:TR?=	NEjJR5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
8-MG-BA	MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3SxNmlEPTB;MT6yPFg3PiEQvF2=	NGrINmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
LP-1	M1LaWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIj4WHNKSzVyPUGuNlk6PDdizszN	MkDCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
LS-411N	NXTUXFRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkTrTWM2OD1zLkOwPVk5KM7:TR?=	Mn7KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
CAL-148	M1rQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NV:5[2ZGUUN3ME2xMlMzPTR{IN88US=>	M4LlNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-H2171	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWTJR\|UxRTFwM{S1NFIh\|ryP	MnLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
JiyoyeP-2003	NETadmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXvqdZNlUUN3ME2xMlM2OzlizszN	MnzDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NCI-H2107	Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXPJR\|UxRTFwM{W4PFMh\|ryP	NXm3RpBkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
BB30-HNC	NHzqdFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXjvPHFGUUN3ME2xMlM5QTd6IN88US=>	NVTE[2hqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
K-562	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M164Z2lEPTB;MT6zPVIyQSEQvF2=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
PSN1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHvBUJZKSzVyPUGuOFIzQDdizszN	NEDxcVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
HCC2157	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnTETWM2OD1zLkSyOlkyKM7:TR?=	NUnaXHNpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
SBC-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3HSe2lEPTB;MT60Nlc1OSEQvF2=	NIG4XoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
MC116	M4e3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoDUTWM2OD1zLkSzOlE2KM7:TR?=	Mm\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
KARPAS-422	NH\IOVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{LtS2lEPTB;MT60OVM2QCEQvF2=	M4PjflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
LB996-RCC	M{XX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYPJR\|UxRTFwNEexNFMh\|ryP	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
MSTO-211H	NF64c4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3rxZWlEPTB;MT60O\|k5PyEQvF2=	NWnObWdkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
BT-474	MorOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVPJR\|UxRTFwNUG3OlQh\|ryP	MnXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
A388	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlO0TWM2OD1zLkWxPVQ2KM7:TR?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
SJSA-1	M1fF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYrlOI5kUUN3ME2xMlUzOjZizszN	NWjDTo8xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
COLO-829	NITWOmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnLaTWM2OD1zLkWzOVY1KM7:TR?=	NG\aXGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
KM-H2	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHnsUYRKSzVyPUGuOVY3PyEQvF2=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
GR-ST	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUjGcJRyUUN3ME2xMlU3QDJizszN	M134Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
RPMI-8866	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MoTnTWM2OD1zLk[wNVQ1KM7:TR?=	M{PGcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
KG-1	M4TvXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2PaR2lEPTB;MT62NVkxOSEQvF2=	NFzUd409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H82	M2\5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmSyTWM2OD1zLk[zOFA3KM7:TR?=	M1vzRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
LB1047-RCC	NWHEbYhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MV\JR\|UxRTFwNkO0OVkh\|ryP	NHnkdGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
KM12	NVP0PYtST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlHMTWM2OD1zLk[0O{DPxE1?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NB5	MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUHJR\|UxRTFwNkW2O\|ch\|ryP	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
HDLM-2	M1PJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2Di[2lEPTB;MT62PFI5OSEQvF2=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
KU812	NF7R[ppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MX\JR\|UxRTFwNkm2NFUh\|ryP	MontQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
DB	MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NETXbndKSzVyPUGuO\|A{PTNizszN	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
HD-MY-Z	NF\KVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MoXxTWM2OD1zLke1NlM1KM7:TR?=	NXvzbGJRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
KURAMOCHI	MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmTBTWM2OD1zLke3NlA4KM7:TR?=	MkWyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
ETK-1	NXXaSnRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEPBSGpKSzVyPUGuO\|g5PzlizszN	Mn62QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
SK-UT-1	NHHLfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHnl[YlKSzVyPUGuO\|k{QDhizszN	NITLeYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
HUTU-80	NFTzeFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGfXWJNKSzVyPUGuO\|k2ODhizszN	NVvDVGNmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
ES7	M1fLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYOzW2dMUUN3ME2xMlgxOzB{IN88US=>	NGLZeJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
SW872	NF7xPYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHrlTFlKSzVyPUGuPFE{QTVizszN	MmP5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
TK10	NF;BbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXfJR\|UxRTFwOEOxNFgh\|ryP	M3Tkb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
LB831-BLC	M4rw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NELreGlKSzVyPUGuPFM2PjNizszN	MmW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
TE-9	M4KxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlzsTWM2OD1zLki0OFIzKM7:TR?=	M3jiXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
MLMA	MmjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MYDJR\|UxRTFwOEiyN\|Qh\|ryP	NYe2c3VQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
D-542MG	MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4Tx[WlEPTB;MT64PVM4OyEQvF2=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
EW-16	MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFW5Z2FKSzVyPUGuPVI4OiEQvF2=	M3rIRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
LOXIMVI	M2jPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGDIU4hKSzVyPUGuPVMzQCEQvF2=	NYfnOpdQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
GB-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHfnZoVKSzVyPUGuPVM5PjZizszN	NHrtfJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
IST-SL2	NI\iOYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NV\nTWVCUUN3ME2yMlAxOjZ{IN88US=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
LAN-6	NITXbmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHjJfFJKSzVyPUKuNFE6PjZizszN	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H510A	NEf6[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{eySmlEPTB;Mj6wOFUxOiEQvF2=	M2DvR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-H1092	M1;QOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHLvUplKSzVyPUKuNFUyOjRizszN	NI\1R449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
HT	NGLXcHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NH7FPFNKSzVyPUKuNVA1PTRizszN	NFn5ZYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
RL95-2	M{HNZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYLle2lOUUN3ME2yMlEyPDh{IN88US=>	NIHn[4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H1355	M{nTRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYTJR\|UxRTJwMUG3PVIh\|ryP	NWD6bpFxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NCI-H720	MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVHJR\|UxRTJwMU[4O\|Mh\|ryP	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H1522	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWriOHZrUUN3ME2yMlIyPzJ\|IN88US=>	MofUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
LB373-MEL-D	M1vJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWP0d3NmUUN3ME2yMlI3QTB{IN88US=>	NITO[4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
DG-75	NV\kZmpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHXaS25KSzVyPUKuNlcyPDhizszN	NWX4d4w{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
ML-2	M3T2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYXJR\|UxRTJwM{K4OVUh\|ryP	NVnHbIF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
SF126	MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4jre2lEPTB;Mj6zN\|A6PCEQvF2=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
MPP-89	NHvRdHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1fiPWlEPTB;Mj6zN\|E1PSEQvF2=	M4Gye\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-H345	NFqwTXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWDQZVBmUUN3ME2yMlM{Ojd5IN88US=>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
LS-123	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUnSS3ZKUUN3ME2yMlM1QTN4IN88US=>	M{CzblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NB10	NEHUdWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlXXTWM2OD1{LkSxNFkzKM7:TR?=	NWLNPYV6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
CGTH-W-1	NIDHfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWn3NFV5UUN3ME2yMlQzOjZ5IN88US=>	NXLLU25nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
CP66-MEL	NILqS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWnJR\|UxRTJwNEe3O{DPxE1?	NGPTNoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
L-428	NIH1NW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1PaXGlEPTB;Mj60PFUzOSEQvF2=	NX3uWVN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
DMS-79	MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIXqfnlKSzVyPUKuOVQyODNizszN	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H1882	M2K3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXTmT2FpUUN3ME2yMlY4PTZ{IN88US=>	MkfCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
KGN	NUex[YIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHr5W3JKSzVyPUKuO\|Y5PzZizszN	NHXyUpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
EW-1	NVf6R2UyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NH\CTFhKSzVyPUKuO\|cxQDNizszN	NVjDU3RLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
U-266	NHPZd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVXiOG5uUUN3ME2yMlg1QDJ\|IN88US=>	NEjNOVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
COLO-320-HSR	M2DUUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXLJR\|UxRTJwOEW2OFEh\|ryP	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
KMOE-2	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHTxNWJKSzVyPUKuPFc4OTFizszN	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
BB49-HNC	NU\3PFdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2roSGlEPTB;Mj65NlQ5KM7:TR?=	NYq3R2h3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
GI-1	MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUjJR\|UxRTJwOUK5OVch\|ryP	NUHEVZQ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NCI-H1304	NFP2eZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGiy[XNKSzVyPUOuNFA2OTFizszN	NEW0WXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H2227	NWjTRop7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXjJR\|UxRTNwMEKwO\|kh\|ryP	NFPmOpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
U-87-MG	M1LPVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWm3[Xo4UUN3ME2zMlA{PTF\|IN88US=>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H747	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVvJR\|UxRTNwMEWyNFYh\|ryP	NIf6[Vc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
CTB-1	MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NF\mcmpKSzVyPUOuNFU{PzZizszN	NEnFO5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
RPMI-8226	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4W4emlEPTB;Mz6xOFM4QCEQvF2=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H2141	NYDyWppoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NILWSWxKSzVyPUOuNVY2PjZizszN	NVfiRYQ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
IST-MES1	NXLMS5U5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoTkTWM2OD1\|LkG4Nlc6KM7:TR?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
TE-5	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWHXSnl4UUN3ME2zMlIyOzR{IN88US=>	NWXSVmprRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
UACC-257	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmjKTWM2OD1\|LkSzOlU6KM7:TR?=	M3GzTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
SK-N-FI	MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXLJR\|UxRTNwNEWyNlch\|ryP	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
MFH-ino	M2n4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{nXSGlEPTB;Mz60OlU5QSEQvF2=	NEftOFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
SF268	NIX5cGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1nwN2lEPTB;Mz60PFE4PCEQvF2=	NF3ubnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
TE-12	NWXEd\|k2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXHJR\|UxRTNwNUG2PVkh\|ryP	NYHveItjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NB6	MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NEe0bHFKSzVyPUOuOVU2PjNizszN	NUjlb3N4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
DJM-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWLtR2s1UUN3ME2zMlU6QDl7IN88US=>	NUTOfnJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
MZ1-PC	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUHJR\|UxRTNwNkG2NlQh\|ryP	MoHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
OCI-AML2	NV3Ecm5xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX\h[2hQUUN3ME2zMlYzPjdzIN88US=>	NH7VZVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H1155	MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MV;JR\|UxRTNwN{C5OFch\|ryP	NXTlUGJURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
RKO	M1Xxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3;RbmlEPTB;Mz63O\|E5QSEQvF2=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
ECC4	NFTjc\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXTJR\|UxRTNwOUexPVUh\|ryP	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
BB65-RCC	M4G0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NISyfIpKSzVyPUOuPVc2PDdizszN	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
EB-3	M3r1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmK4TWM2OD1\|Lkm5OlM{KM7:TR?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
SHP-77	MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NH\WemNKSzVyPUSuNFA2OjRizszN	NHHRO2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H2196	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWfmR\|FJUUN3ME20MlA2PjJ3IN88US=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
GI-ME-N	NXnKSY9FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{TvNmlEPTB;ND6wOlM6QSEQvF2=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
MN-60	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NEO5XFZKSzVyPUSuNVA5PyEQvF2=	NFjEXmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H1694	M{LuNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1vpOGlEPTB;ND6xN\|QxPSEQvF2=	MkjRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
LU-65	M2\jVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXTJR\|UxRTRwMUWzN\|Ih\|ryP	NHvyb2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H1436	M1TtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4rvOWlEPTB;ND6xPFM{OyEQvF2=	MorSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
KINGS-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mk\UTWM2OD12LkOxOFMzKM7:TR?=	MnfMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
GT3TKB	MkTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NGPuXnlKSzVyPUSuN\|MzPjhizszN	NEfic5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
Becker	MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NG\GfJdKSzVyPUSuN\|c{OTJizszN	MmH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
HCC1187	NIP3UVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUDJR\|UxRTRwOEm2OVch\|ryP	M{i4VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
D-502MG	M1rnS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWi2U4ZWUUN3ME21MlAxPDF4IN88US=>	NH7oPIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
VA-ES-BJ	M2\5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4HNOWlEPTB;NT6xN\|c4QCEQvF2=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NB7	NHmzV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NF3tfXhKSzVyPUWuNVQyOTJizszN	NYnQZ5RIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
SW962	NVrJSGtvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3G5TmlEPTB;NT6zPFgyPCEQvF2=	NW[0RnNWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
no-11	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUO0VWc1UUN3ME21Mlc3OzR\|IN88US=>	M4[1TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
KNS-81-FD	NFflXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Moi5TWM2OD13LkmwOlk1KM7:TR?=	NH7ZSXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
COLO-684	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3T4VmlEPTB;NT65PVQ6PCEQvF2=	NFTucVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
D-263MG	NIPpcGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnfjTWM2OD14LkC4PFk2KM7:TR?=	NVjMSGlyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
EW-24	NX\SV5ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHnNNopKSzVyPU[uNlg2OSEQvF2=	NWm1PHJxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
TE-10	M1PKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGPPNJpKSzVyPU[uOFI3OjNizszN	NG[4Wmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
EKVX	MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3XpW2lEPTB;Nj60OlMzOSEQvF2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H1648	NEHnS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYPJR\|UxRTZwNke1OVch\|ryP	NH3UbZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
LB771-HNC	NGWye2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIC4PXlKSzVyPU[uPVI{ODFizszN	Mlr3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
SK-MEL-1	MkDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmPJTWM2OD16LkGzNVY3KM7:TR?=	NIG5PG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
COLO-668	NEHBWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVjqPGFrUUN3ME24MlI4Pzh4IN88US=>	MlTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
EW-12	NV7LdI1lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVjTV\|NHUUN3ME24MlQxQDB\|IN88US=>	NGLOTWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
A253	NGnZTHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MoPrTWM2OD16Lki0OlYyKM7:TR?=	M3KxOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-H2126	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3HFPWlEPTB;OD64PVMyQSEQvF2=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
Calu-6	M1XpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NV;TZVVNUUN3ME24Mlk6ODR{IN88US=>	NI[wU5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H23	NIPWfoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{LtV2lEPTB;OT6xO\|c1PiEQvF2=	NGLTNnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
WSU-NHL	M{DzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUfrc3JrUUN3ME25Mlc4PDd6IN88US=>	M2OwSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
MMAC-SF	NWS2V3pkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnLITWM2OD17Lkm3PVA1KM7:TR?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
SK-LMS-1	NEPUUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUOzNHhDUUN3ME2xNE4zQDN2IN88US=>	NHPGfFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
GCIY	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUm1fXJDUUN3ME2xNE42QTJ2IN88US=>	NH[1[FE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
TE-15	NXHqZox6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkXXTWM2OD1zMT62NFA1KM7:TR?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
EoL-1-cell	NF7NRpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mki1TWM2OD1zMT63OlgzKM7:TR?=	NUi0eWN6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NCI-H2081	MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlzZTWM2OD1zMT63O\|g3KM7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
EW-3	NWLEVVNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MX7JR\|UxRTF{LkK0OlMh\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
CAS-1	NVnheZBNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWruTINOUUN3ME2xNk4{PjNzIN88US=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
C2BBe1	NHyxbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVjJR\|UxRTF{Lk[xN\|Eh\|ryP	MnfEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
D-247MG	NIjOZoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1fofWlEPTB;MUKuO\|k2OiEQvF2=	NUT5cXdyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NCI-SNU-5	NH\MOVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1nz[WlEPTB;MUKuPFAyOyEQvF2=	NYnk[FZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
LS-1034	MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mki2TWM2OD1zND6zPVc2KM7:TR?=	M2L6XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
EW-18	NFzWPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2\3SmlEPTB;MUSuOFQ5KM7:TR?=	NEPUU2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
Raji	NHHRXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIjSZ4VKSzVyPUG0MlUxPDlizszN	MnHoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
D-283MED	MoXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MljHTWM2OD1zND62NlcyKM7:TR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
MZ2-MEL	MmjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2rqVWlEPTB;MUSuPVY6PiEQvF2=	Mn7rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NCI-SNU-16	NI[xbJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MU\JR\|UxRTF3LkS2N\|Mh\|ryP	M3uwT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
P30-OHK	NIfJT2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MV7JR\|UxRTF5Lke4N\|Eh\|ryP	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
RXF393	M{K2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3XuW2lEPTB;MUmuNFE5PiEQvF2=	MljHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NCI-H1395	NXjK[HVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MX\JR\|UxRTJyLk[3NFMh\|ryP	M2TBUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
U-698-M	M3z0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYjJR\|UxRTJyLkewO\|Uh\|ryP	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-SNU-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3XYW2lEPTB;MkCuO\|IzOyEQvF2=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
SW684	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUXaT4hwUUN3ME2yNU4yPzF4IN88US=>	M{HudFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-H716	NX63XmFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlzKTWM2OD1{MT6zNVU1KM7:TR?=	NEPK[XE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
JVM-2	M3fj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{XFdGlEPTB;MkGuOFE{OyEQvF2=	NFjjb4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H1581	M4PKZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M33yN2lEPTB;MkKuOFE1QCEQvF2=	NFnqT4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
CA46	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mn3XTWM2OD1\|MT62PVM3KM7:TR?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
SNB75	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVPHS5ZOUUN3ME2zN{43PTB\|IN88US=>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
KNS-42	M1PaWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3[0TWlEPTB;M{WuPVYzPCEQvF2=	NXv4emdnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
TUR	NY\EZ4JxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXTQdXNYUUN3ME2zOk4xPTJzIN88US=>	M{DPb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
REH	NHXoPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFXtNXJKSzVyPUO3MlgzOTFizszN	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
EW-22	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MV7JR\|UxRTR{LkK4PFUh\|ryP	M2T2SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-H446	NWj6cY5DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1;R[WlEPTB;NEKuO\|g2OyEQvF2=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
ES3	MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mn;GTWM2OD12Mz6xN\|M6KM7:TR?=	NULJSY9[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
EW-11	NVy1NHVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmHYTWM2OD12ND64NlE5KM7:TR?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
RH-1	NVrrT2tNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlS0TWM2OD12Nz61PFEzKM7:TR?=	MmixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
HepG2	Mlq0SpVv[3Srb36gZZN{[Xl?			NGTtXlFKdmirYnn0bY9vKG:oIHj1cYFvKEincFeyJINmdGy\|LDDJR\|UxKD1iMD6wNFA6KM7:TT6=	NWHQ[Hc1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOFc2PTRpPkG4NlQ4PTV2PD;hQi=>
HCT116	MmLFRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M3myd\|Q5KGi{cx?=	NV7qeVNySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOSEQvF2u	NHvCRVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkewOVAzOid-MkK3NFUxOjJ:L3G+
A549	M4nKbmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MXS0PEBpenN?	MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMTFOwG0v	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjdyNUCyNkc,OjJ5MEWwNlI9N2F-
HEK293	NFzZOnhHfW6ldHnvckBie3OjeR?=			NGryXVFKdmirYnn0bY9vKG:oIHj1cYFvKENvdHXycYlv[WxiRlzBS{11[WepZXSgTGRCSzFiaX6gTGVMOjl\|IHPlcIx{NCCLQ{WwJF0hOC5zMjFOwG0v	NUnCVlRwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0OFE5PDZpPkG5OFQyQDR4PD;hQi=>
HEK293	M4i1SWZ2dmO2aX;uJIF{e2G7			MVHJcohq[mm2aX;uJI9nKEiGQVOxJIlvKEiHS{K5N{Bk\WyuczygTWM2OCB;IECuNVIh\|ryPLh?=	M3TH[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{C4OVY{Lz5zOEOwPFU3OzxxYU6=
SNU16	NGnFOWNHfW6ldHnvckBie3OjeR?=			MVnJcohq[mm2aX;uJI9nKEiGQVOg[pJwdSCqdX3hckBUVlVzNjDj[YxteyxiSVO1NEA:KDBwMkOzJO69VS5?	NXvpVXN1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOFc2PTRpPkG4NlQ4PTV2PD;hQi=>
HEK293	NGrFSY9HfW6ldHnvckBie3OjeR?=			NYrKRXllUW6qaXLpeIlwdiCxZjDoeY1idiCFLYTldo1qdmGuIF\MRWcufGGpZ3XkJGhFSUN{IHnuJGhGUzJ7MzDj[YxteyxiSVO1NEA:KDBwMkWg{txONg>?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR2MUi0Okc,OTl2NEG4OFY9N2F-
U937	MWjGeY5kfGmxbjDhd5NigQ>?			M1jLV2lvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{GgbY4hXTl\|NzDj[YxteyCkeTDpcY12dm:ycnXjbZBqfGG2aX;uJIF{e2G7LDDJR\|UxKD1iMD6zJO69VS5?	MnPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|OEGyN\|goRjF6M{ixNlM5RC:jPh?=
SK-N-BE(2)	MnPKRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NEDhcYQ1QCCqcoO=	MkmxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVSz3OMWJGMDJrIHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjN\|IN88UU4>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDVzMUmwOkc,Ojh3MUG5NFY9N2F-
AGS	NEHS[odCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NFf0dVE4OiCqcoO=	MlK4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDR2OgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwM{Sg{txONg>?	MoXWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5OEeyOlIoRjJ7N{i3NlYzRC:jPh?=
MCF7	M2ntXmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NYjmS3NEPDhiaILz	MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNidILlZZRm\CCob4KgOFghcHK\|IH\vcIxwf2WmIHL5JJJm\nKnc3jl[EBmfmW{eTC5OkBpenNibXXhd5Vz\WRib36g[IF6KDFyIHL5JGxwf3K7IHHzd4F6NCCLQ{WwJF0hOC5\|NTFOwG0v	Mn;sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4MUO2N\|UoRjJ4NkGzOlM2RC:jPh?=
HEK293	NEHKeYZHfW6ldHnvckBie3OjeR?=			NUnIe2VVUW6qaXLpeIlwdiCxZjDoeY1idiCFLYTldo1qdmGuIF\MRWcufGGpZ3XkJGhFSUN\|IHnuJGhGUzJ7MzDj[YxteyxiSVO1NEA:KDBwNDFOwG0v	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR2MUi0Okc,OTl2NEG4OFY9N2F-
HEK293	NYTNb4doTnWwY4Tpc44h[XO\|YYm=			MoP2TY5pcWKrdHnvckBw\iCKRFHDN{BqdiCKRVuyPVMh[2WubIOsJGlEPTBiPTCwMlQh\|ryPLh?=	NXTxVWJkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizNFg2PjNpPkG4N\|A5PTZ\|PD;hQi=>
HEL	Mn7XSpVv[3Srb36gZZN{[Xl?		NHi1S5U{KGi{cx?=	NHz3clJKdmirYnn0bY9vKG:oIHPsZZN{KDFiSFTBR{BqdiCKRVygZ4VtdHNidYPpcochSm:lLVz5d{Ap[WOndInsLU1CVUNiYYOgd5Vje3S{YYTlJJBz\WmwY4XiZZRm\CCob4KgN{BpenNiZn;scI94\WRiYomgd5Vje3S{YYTlJIFl\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IEOgbJJ{KGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OCB;IECuOFMh\|ryPLh?=	M2HBcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUGxPVA3Lz5{OEWxNVkxPjxxYU6=
PC3	MmH2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mn\xOFghcHK\|	MoPYS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCJSUWwJF0hOC52MzFOwG0v	NIfLOGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO5OVE2OCd-MkizPVUyPTB:L3G+
HEL	NWjCfYVZSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NFHvclk4OiCqcoO=	MWfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiHTDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC52NDFOwG0v	NGDlbpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe4O\|I3Oid-Mkm3PFczPjJ:L3G+
MOLT4	MmPvRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NW\aSVJ[PzJiaILz	NGLsWWVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUHQ1KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlQ2KM7:TT6=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd6N{K2Nkc,Ojl5OEeyOlI9N2F-
HCT116	M4jCWGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MUS3NkBpenN?	MlvNRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPDT{05KGG\|c3H5MEBKSzVyIE2gNE41PyEQvF2u	M{HRbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkCyN\|k4Lz5{OUKwNlM6PzxxYU6=
HEL	M4G3VWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NXW0XHJNPDhiaILz	MVzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFjFUEBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD60PEDPxE1w	NGWwOnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEWxNVkxPid-Mki1NVE6ODZ:L3G+
HCT116	MXvGeY5kfGmxbjDhd5NigQ>?			M1K0OWlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWMUG2JINmdGy\|LDDJR\|UxKD1iMD61JO69VS5?	Mmq0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NEe1OVQoRjF6MkS3OVU1RC:jPh?=
U937	MlfwRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NIfMV5k4OiCqcoO=	NXnafIpWSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPVM4KGOnbHzzJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuOVUh\|ryPLh?=	NELtZY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm1N\|czOid-MkW5OVM4OjJ:L3G+
U937	MXTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NIDnOHc4OiCqcoO=	M1PHW2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUmzO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIFnfGW{IEeyJIhzeyCkeTDNWHQu[mG\|ZXSgZZN{[XluIFnDOVAhRSByLkW1JO69VS5?	M3e4RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEe0N\|I3Lz5{NUi3OFMzPjxxYU6=
HCT116	NGG3[mxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NWXGO3dGOiCmYYnz	MWfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgNkBl[Xm\|IHL5JG1VXCCjc4PhfUwhT0l3MDC9JFAvPiEQvF2u	NUnIcWI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFE{QTRpPkKyOVQyOzl2PD;hQi=>
HL60	MWHGeY5kfGmxbjDhd5NigQ>?		M{HGUFMhcHK\|	NGGycmZKdmirYnn0bY9vKG:oIHPsZZN{KDFiSFTBR{BqdiCqdX3hckBJVDZyIHPlcIx{KHW\|aX7nJGJw[y2DYz3MfZMuSU2FIHHzJJN2[nO2cnH0[UBqdmO3YnH0[YQh\m:{IEOgbJJ{KG[xbHzve4VlKGK7IIP1ZpN1emG2ZTDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiB\|IHjyd{BjgSCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLk[yJO69VS5?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDRzNUCwPUc,Ojh2MUWwNFk9N2F-
MOLT4	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MnjCOFghcHK\|	M360[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MWFQh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuOlUh\|ryPLh?=	MljDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3MUG5NFYoRjJ6NUGxPVA3RC:jPh?=
HCT116	Ml6yRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			NGDqe2dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{whUUN3MDC9JFAvPjdizszNMi=>	NI\VUHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe0NlQ6Pid-MkG3OFI1QTZ:L3G+
HCT116	MmX2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			NEPlSXRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdixiSVO1NEA:KDBwNkeg{txONg>?	M{PsW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNkWwNlIyLz5{MU[1NFIzOTxxYU6=
HCT116	NX3nOoVrSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NXPEOJR5PzJiaILz	NHzPVZRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGC1N{BmgHC{ZYPzbY5oKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliY3XscJRqfGW{LXLseYUh[2WubDD2bYFjcWyrdImgZZN{[XluIFPDOVAhRSByLkeg{txONg>?	NIT5cIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUS0NVg1Pid-MUm0OFE5PDZ:L3G+
HCT116	NWPHblk1SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			NIi2fY1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{BjgSCFZXzsWIl1\XJvQnz1[UBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwNzFOwG0v	M1vBVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{ewN\|c{Lz5zOEO3NFM4OzxxYU6=
HEK293T	NXrE[JF2TnWwY4Tpc44h[XO\|YYm=		NVnBUWhQOSCqch?=	MlvOTY5pcWKrdHnvckBw\iCITFHHMZRi\2enZDDISGFEOiBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDISWszQTOWIHPlcIx{KHW\|aX7nJIFk\XS7bHH0[YQhdHm\|aX7lJJNq\GViY3jhbY4h[XNic4Xid5Rz[XSnIHHmeIVzKDFiaIKgZpkh[2:ub4LpcYV1emmlIHTleIVkfGmxbjDiZZNm\CCjc4PhfUwhUUN3MDC9JFAvPzRizszNMi=>	NIPLNJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PVg5PSd-MkmyPFk5QDV:L3G+
ML1	NV[xUIF[SW62aYT1cY9zKGG\|c3H5			MnrhRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViTVyxJINmdGy\|LDDJR\|UxKD1iMD63OUDPxE1w	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTV\|NEWzOEc,OTl3M{S1N\|Q9N2F-
HCT116	NGDObHBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NV7BfoxzOyCmYYnz	NIrH[VJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjCzJIRigXNiYomgW3NVNTFiYYPzZZktKEmFNUCgQUAxNjd4IN88UU4>	MmPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|MkGyNVUoRjJ{M{KxNlE2RC:jPh?=
U937	M32yW2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NUn4UlNZPDhiaILz	NHXuXGRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW5N\|ch[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuO\|ch\|ryPLh?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDRzNUCwPUc,Ojh2MUWwNFk9N2F-
HCT116	M1HER2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NFXsXFU4OiCqcoO=	NILOOoZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxiZ4Lve5RpKGGodHXyJFczKGi{czDifUBOXFRvYnHz[YQh[XO\|YYmsJGlEPTBiPTCwMlc5KM7:TT6=	NGq3RmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3OFMzPid-MkW4O\|Q{OjZ:L3G+
K562	MYDGeY5kfGmxbjDhd5NigQ>?		MX:xNEBucW6\|	MVPJcohq[mm2aX;uJI9nKEuGQVOzJIlvKGi3bXHuJGs2PjJiY3XscJMhfXOrbnegX\|NJZWGlZYT5cIF1\WRiaHnzeI9v\SCjczDzeYJ{fHKjdHWgbY5kfWKjdHXkJIZweiBzMDDtbY5{KGK7IHzpdZVq\CC\|Y3nueIltdGG2aX;uJINwfW62aX7nJI1mfGixZDygTWM2OCB;IECuO\|kh\|ryPLh?=	MmjQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4OEG0NFQoRjJ4NkixOFA1RC:jPh?=
HCT116	MmrvR5l1d3SxeHnjbZR6KGG\|c3H5		M2GwdlMh\GG7cx?=	NGn0N41EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhOyCmYYnzJIJ6KFeVVD2xJIF{e2G7LDDJR\|UxKD1iMD64JO69VS5?	M3fQdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEWyNlI3Lz5{MES1NlIzPjxxYU6=
SKBR3	Mn;ORY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			M17NeWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1vCVlMh[2WubIOsJGlEPTBiPTCwMlg4KM7:TT6=	MkDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NEe1OVQoRjF6MkS3OVU1RC:jPh?=
Sf9	NXTCbogzTnWwY4Tpc44h[XO\|YYm=		NULZfYR7OyCqcoO=	M{TPWWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR{11\XKvaX7hcEBJcXNvdHHn[4VlKEiGQVOxNUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDT[lkh[2WubIOgeZNqdmdiQXOtRZJoNUeueT3MfZMpSWNrLVHNR{BieyC\|dXLzeJJifGVicILleJJm[XSnZDDmc5IhOyCqcoOg[o9tdG:5ZXSgZpkhe3Wkc4TyZZRmKGGmZHn0bY9vKGGodHXyJFMxKG2rboOgZpkh\my3b4LvcYV1emmlIH3leIhw\CxiSVO1NEA:KDBwOTFOwG0v	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDVyMUWxOEc,Ojh3MEG1NVQ9N2F-
S2	NYTDNmhLTnWwY4Tpc44h[XO\|YYm=			MV\Jcohq[mm2aX;uJI9nKFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDISGFEOSCneIDy[ZN{\WRiaX6gSJJwe2:yaHnsZUBu\Wyjbn;nZZN1\XJiU{KgZ4VtdHNuIFnDOVAhRSByLkm0JO69VS5?	M3jpdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{G3OFUxLz5zOUOxO\|Q2ODxxYU6=
HEK293T	NHPqPVJHfW6ldHnvckBie3OjeR?=		MX6xJIhz	NUnRZYpYUW6qaXLpeIlwdiCxZjDoeY1idiCITFHHMZRi\2enZDDISGFEOSCneIDy[ZN{\WRiaX6gTGVMOjl\|VDDj[YxteyC3c3nu[{Bi[2W2eXzheIVlKGy7c3nu[UB{cWSnIHPoZYlvKGG\|IIP1ZpN1emG2ZTDh[pRmeiBzIHjyJIJ6KGOxbH;ybY1mfHKrYzDk[ZRm[3Srb36gZoF{\WRiYYPzZZktKEmFNUCgQUAyNjB5IN88UU4>	M2TFNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki5PFg2Lz5{OUK4PVg5PTxxYU6=
A549	NXnlTIZySW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MXm3NkBpenN?	NUiwRmhESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQOVMh\XiycnXzd4lv\yCDNUS5JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSClZXzseIl1\XJvYnz1[UBk\WyuII\pZYJqdGm2eTDhd5NigSxiQ1O1NEA:KDFwMjFOwG0v	M1\yXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NESxPFQ3Lz5zOUS0NVg1PjxxYU6=
A549	MmPrRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			NH7IOoZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZpkhS2WubGTpeIVzNUKudXWgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjJizszNMi=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN5MEO3N{c,OTh\|N{CzO\|M9N2F-
HEK293T	MUHGeY5kfGmxbjDhd5NigQ>?		MnXKNUBpeg>?	MnTYTY5pcWKrdHnvckBw\iCqdX3hckBHVEGJLYTh[4dm\CCKRFHDN{BmgHC{ZYPz[YQhcW5iSFXLNlk{XCClZXzsd{B2e2mwZzDhZ4V1gWyjdHXkJIx6e2mwZTDzbYRmKGOqYXnuJIF{KHO3YoP0doF1\SCjZoTldkAyKGi{IHL5JINwdG:{aX3leJJq[yCmZYTlZ5Rqd25iYnHz[YQh[XO\|YYmsJGlEPTBiPTCxMlI{KM7:TT6=	NYnYc3BLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFk5QDVpPkK5Nlg6QDh3PD;hQi=>
HEL	MkXLRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NEX4d2E1QCCqcoO=	NVfENoZPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBJTUxiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFEvOjlizszNMi=>	NXPEXWxWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NVUxODlpPkK4OFE2ODB7PD;hQi=>
G401	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M4T3UFczKGi{cx?=	M2fib2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iR{SwNUBk\WyuczDh[pRmeiB5MjDodpMh[nliY3XscJRqfGW{LXLseYUh[2WubDD2bYFjcWyrdImgZZN{[XluIFPDOVAhRSBzLkOg{txONg>?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR2MUi0Okc,OTl2NEG4OFY9N2F-
G401	NFfYNYJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			MV7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEd2MEGgZ4VtdHNiYomgR4VtdFSrdHXyMWJtfWViY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxMlMh\|ryPLh?=	MnqzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|N{CzO\|MoRjF6M{ewN\|c{RC:jPh?=
Sf9	MnrlSpVv[3Srb36gZZN{[Xl?		NHzlNpo{KGi{cx?=	MUHJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFOteIVzdWmwYXygTIl{NXSjZ3fl[EBJTEGFMUGgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU3[5JINmdGy\|IIXzbY5oKEGlLVHy[{1IdHlvTInzLGFkMS2DTVOgZZMhe3Wkc4TyZZRmKHC{ZYTy[YF1\WRiZn;yJFMhcHK\|IH\vcIxwf2WmIHL5JJN2[nO2cnH0[UBi\GSrdHnvckBi\nSncjCzNEBucW6\|IHnuJJBz\XOnbnPlJI9nKDBwMjD1UUBUSUiDIHL5JIYtKEmFNUCgQUAyNjNizszNMi=>	NY\qdIF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1NFE2OTRpPkK4OVAyPTF2PD;hQi=>
K562	MnnuRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MonROFghcHK\|	NXHDUoFKSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxMlMzKM7:TT6=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDVzMUmwOkc,Ojh3MUG5NFY9N2F-
Huh7	MWnBcpRqfmm{YXygZZN{[Xl?		M3TlS\|Mh\GG7cx?=	NXy3O2lESW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEOYIHflco91gXCnIEHiJIlv\mWldHXkJIlvKGi3bXHuJGh2cDdiY3XscJMh[W[2ZYKgN{Bl[Xm\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NEA:KDFwNDFOwG0v	NGj6W5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS5NFcxOCd-MkW0PVA4ODB:L3G+
MDA-MB-231	MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUPZUJdZPDhiaILz	NXTXVFZ3T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjC0PEBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NEA:KDFwNEGg{txONg>?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN7NUG1NEc,Ojh\|OUWxOVA9N2F-
K562	M4fCPWZ2dmO2aX;uJIF{e2G7		MmrtNVAhdWmwcx?=	M1TUZ2lvcGmkaYTpc44hd2ZiS1TBR\|EhcW5iaIXtZY4hUzV4MjDj[YxteyC3c3nu[{BcO0ifYXPleJlt[XSnZDDobZN1d26nIHHzJJN2[nO2cnH0[UBqdmO3YnH0[YQh\m:{IEGwJI1qdnNiYomgcIlyfWmmIIPjbY51cWyuYYTpc44h[2:3boTpcochdWW2aH;kMEBKSzVyIE2gNU41QCEQvF2u	MoK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4OEG0NFQoRjJ4NkixOFA1RC:jPh?=
HL60	MmLRRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MmGwOFghcHK\|	NHvNR\|VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGuOVIh\|ryPLh?=	NV\TXWk6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NVUxODlpPkK4OFE2ODB7PD;hQi=>
HeLa	MoXwRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			NGrpXWFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGhmVGFiY3XscJMh[nliYXzhcYFzKGKudXWgZZN{[XluIFnDOVAhRSBzLkW4OFg6KM7:TT6=	NF;K[5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[wOlM4OCd-MUe2NFY{PzB:L3G+
HeLa	M{\LWGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NWGwd3B7PzJiaILz	NGq5NpFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjlUIEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPDT{05KGG\|c3H5MEBKSzVyIE2gNU43KM7:TT6=	NVjId4FTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyNFI{QTdpPkK5NlAzOzl5PD;hQi=>
K562	NV;0NldHSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MXK0PEBpenN?	MYLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDFwNkig{txONg>?	NUi4[\|VQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NVUxODlpPkK4OFE2ODB7PD;hQi=>
HeLa	MWfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MkXuO\|IhcHK\|	NXfVW401SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQOVMu\GWoaXPp[Y51KEinTHGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOnbHz0bZRmei2kbIXlJINmdGxidnnhZoltcXS7IHHzd4F6NCCFQ{WwJF0hOS56IN88UU4>	NUTDOZVzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0OFE5PDZpPkG5OFQyQDR4PD;hQi=>
HeLa	Mo\TRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			Mn6zRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZVzhJINmdGy\|IHL5JGNmdGyWaYTldk1DdHWnIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNU45KM7:TT6=	NVToWHU6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizO\|A{PzNpPkG4N\|cxOzd\|PD;hQi=>
HCT116	MYHGeY5kfGmxbjDhd5NigQ>?		NFLyO3MyQCCqcoO=	MXrJcohq[mm2aX;uJI9nKEiGQVOgbY4hcHWvYX6gTGNVOTF4IHPlcIx{KHW\|aX7nJGJw[y2OeYOgLIVxe2mub36tRYMqNUGPQzDhd{B{fWK\|dILheIUheHKndILlZZRm\CCob4KgNVghcHK\|IH\vcIxwf2WmIHL5JJN2[nO2cnH0[UBi\GSrdHnvckBi\nSncjCzJIhzeyCkeTDmcJVwemW\|Y3XuZ4Uh[XO\|YYmsJGlEPTBiPTCxMlk3KM7:TT6=	NHnW[Iw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO0NFQyOyd-MkizOFA1OTN:L3G+
DU145	MVvDfZRwfG:6aXPpeJkh[XO\|YYm=			Ml[3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMjFOwG0v	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF\|MUK0PEc,OTlzM{GyOFg9N2F-
K562	MX3GeY5kfGmxbjDhd5NigQ>?			M3fpNmlvcGmkaYTpc44hd2ZiaIXtZY4hcGm\|dH;u[UBl\WGlZYT5cIF{\SBqbXn4eJVz\SCxZjDISGFEOSCjbnSgTGRCSzJrIIDy[ZBiemWmIH\yc40hUzV4MjDldpl1cHKxbHX1b4VucWFiY3XscJMvNCCLQ{WwJF0hOiEQvF2u	NWq4c\|NtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK0NVk{QDBpPkGyOFE6OzhyPD;hQi=>
K562	NEfFTVlHfW6ldHnvckBie3OjeR?=			NF;aNJVKdmirYnn0c5J6KGGldHn2bZR6KGGpYXnud5QhUGm\|dH;u[UBl\WGlZYT5cIF{\SBqSFTBR{khcW5iSzC1OlIh\XK7dHjyc4xmfWunbXnhJINmdGy\|LDDJR\|UxKD1iMjFOwG0v	MlraQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTR3OUK0O\|MoRjF2NUmyOFc{RC:jPh?=
HCT116	NVuwe2p4SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MlnCOFghcHK\|	M1r2SGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCyMlA{KM7:TT6=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN2MESxN{c,Ojh\|NEC0NVM9N2F-
HCT116	NXXYWFNKSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NHfxWHo1QCCqcoO=	MmDiRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKuNFch\|ryPLh?=	NW\hRmpTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NVUxODlpPkK4OFE2ODB7PD;hQi=>
NCI-H661	M4PheWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NHznNWI4OiCqcoO=	MoK4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFY3OSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxiZ4Lve5RpKGGodHXyJFczKGi{czDifUBOXFRvYnHz[YQh[XO\|YYmsJGlEPTBiPTCyMlE6KM7:TT6=	NWrzZ25TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|Q{OjZpPkK1PFc1OzJ4PD;hQi=>
NCI-H661	MoDDRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MorVO\|IhcHK\|	MYXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IOlYyKGOnbHzzJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKuNVkh\|ryPLh?=	MlrpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NUO3NlIoRjJ3OUWzO\|IzRC:jPh?=
SNU-16	MmjkSpVv[3Srb36gZZN{[Xl?			NIHobYVKdmirYnn0c5J6KGGldHn2bZR6KGGpYXnud5QhUGm\|dH;u[UBl\WGlZYT5cIF{\SBqSFTBR{kh\nKxbTDTUnUuOTZiKHj1cYFvKGejc4TybYMh[WSnbn;jZZJkcW6xbXGpJINmdGy\|LDDJR\|UxKD1iMj6xPVQ2QSEQvF2u	M3nyXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2Nk[3NlI4Lz5zNE[2O\|IzPzxxYU6=
Sf9	MlLZSpVv[3Srb36gZZN{[Xl?		MUCxO{BpenN?	NWjuSVh[UW6qaXLpeIlwdiCxZjDIbZM3NXSjZ3fl[EBJTEGFMz;TUXJVKCh\|OUWgeI8hPDh7IILld4llfWW\|KTCoeY5sdm:5bjDvdolocW5rIHPvMYV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDz[lkh[2WubIOgeZNqdmdiKF\BUUkudGGkZXzl[EBi[2W2eXzheIVlKHCncITp[IUhe3Wkc4TyZZRmKGGodHXyJFE4KGi{czDifUBk[WyrcHXyJI1q[3KxZnz1bYRq[yCvb3LpcIl1gSC\|aHnmeEBie3OjeTygTWM2OCB;IEKuN\|EzODZizszNMi=>	M{j0ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMUe5O\|Q6Lz5\|MEG3PVc1QTxxYU6=
ACHN	M2DlZWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NX7VOoJ7PzJiaILz	M37QZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQVPIUkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMj60JO69VS5?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd6N{K2Nkc,Ojl5OEeyOlI9N2F-
SGC7901	MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1nOOVczKGi{cx?=	M3S5PGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNISzd7MEGgZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhX1OWIHT5[UBz\WS3Y4Tpc44h[XO\|YYmsJGdKQTBiPTCyMlUh\|ryPLh?=	NETxNHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2NVM4Pid-MkOwOlE{PzZ:L3G+
MDA-MB-231	MVPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NEDrSYM4OiCqcoO=	NGrMTJFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDJwNUWg{txONg>?	M4m3WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{i3NlYzLz5{OUe4O\|I3OjxxYU6=
MDA-MB-231	NXzKWoszSW62aXPhcoNmeiCjc4PhfS=>		M{nQVVczKGi{cx?=	NV;uXVFGSW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygS2khRSB{Lkig{txONg>?	NUjjcnBpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3OFE5OzRpPkKxO\|QyQDN2PD;hQi=>
A2780	NHrzfFZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M4\DfVczKGi{cx?=	MlrDRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDMke4NEBk\WyuczDh[pRmeiB5MjDodpMh[nliY3XscJRqfGW{LXLseYUh[2WubDD2bYFjcWyrdImgZZN{[XluIFPDOVAhRSB\|IN88UU4>	MmjiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl2NEG4OFYoRjF7NESxPFQ3RC:jPh?=
A2780	MkTzRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			MkXsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDMke4NEBk\WyuczDifUBE\WyuVHn0[ZIuSmy3ZTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFMh\|ryPLh?=	NEH1VIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO3NFM4Oyd-MUizO\|A{PzN:L3G+
HCT116	MWPBcpRq[2GwY3XyJIF{e2G7		MXu3NkBpenN?	MkPCRY51cWOjbnPldkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBIUSB;IEOuNUDPxE1w	NX;1cVY1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3OFE5OzRpPkKxO\|QyQDN2PD;hQi=>
HT-29	MW\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MmKxO\|IhcHK\|	NHmxT5ZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUMVI6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCzMlEh\|ryPLh?=	M4TE[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{i3NlYzLz5{OUe4O\|I3OjxxYU6=
A549	MlXtRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MonWOFghcHK\|	NVLmUmEzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCzMlEyKM7:TT6=	NGT5d3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO0NFQyOyd-MkizOFA1OTN:L3G+
A549	M2rUNWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M3TMXVczKGi{cx?=	MlewR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gN{4yOzRizszNMi=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF2MEm2NUc,OjZzNEC5OlE9N2F-
A2780	M1rhO2Z2dmO2aX;uJIF{e2G7		M1\idlE5KGi{cx?=	NYXnZmc1UW6qaXLpeIlwdiCxZjDISGFEKGmwIHj1cYFvKEF{N{iwJINmdGy\|IIXzbY5oKEKxYz3MfZMhMGWyc3nsc44uSWNrLVHNR{BieyC\|dXLzeJJifGVicILleJJm[XSnZDDmc5IhOThiaILzJIZwdGyxd3XkJIJ6KHO3YoP0doF1\SCjZHTpeIlwdiCjZoTldkA{KGi{czDifUBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUA{NjF3IN88UU4>	M1LIflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{SwOFE{Lz5{OEO0NFQyOzxxYU6=
SW620	MnjXSpVv[3Srb36gZZN{[Xl?			NILMSlJKdmirYnn0bY9vKG:oIHj1cYFvKFOZNkKwJINmdGy\|LDDJR\|UxKD1iMz6yJO69VS5?	MoPnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NEe1OVQoRjF6MkS3OVU1RC:jPh?=
HeLa	MkHOSpVv[3Srb36gZZN{[Xl?		MYCzNEBucW6\|	Mkn4TY5pcWKrdHnvckBw\iCqdX3hckBJTEGFIHnuJGhmVGFiY3XscJMh[W[2ZYKgN\|AhdWmwczDifUBHdHWxcjDk[UBNgXNiZnz1c5Jme2OnbnPlJIF{e2G7LDDJR\|UxKD1iMz6yJO69VS5?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTh6OUO0N{c,OjF6OEmzOFM9N2F-
A549	MWHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			MoLYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|LDDJR\|UxKD1iMz61PEDPxE1w	M1z6SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MkS3OVU1Lz5zOEK0O\|U2PDxxYU6=
K562	M1rJeWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NHHnZpI4OiCqcoO=	NYOwRWxjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCzMlY3KM7:TT6=	NFfPUWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe4O\|I3Oid-Mkm3PFczPjJ:L3G+
A375	M{j0VmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M1PNSlczKGi{cx?=	MmniRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDM{e1JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFQ1utPEBie3OjeTygTWM2OCB;IEOuOlch\|ryPLh?=	NFrLS2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUKwNlM6Pyd-MkmyNFI{QTd:L3G+
MCF7	M1XzS2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MljFOFghcHK\|	NX7rPYhDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC0MlAzKM7:TT6=	MmrIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|NEC0NVMoRjJ6M{SwOFE{RC:jPh?=
MKN45	MojtRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			MUnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2NTkS1JINmdGy\|LDDJR\|UxKD1iND6xOkDPxE1w	NXrHVnZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOFc2PTRpPkG4NlQ4PTV2PD;hQi=>
MCF7	MUfGeY5kfGmxbjDhd5NigQ>?			NXzzWlFxUW6qaXLpeIlwdiCxZjDoeY1idiCPQ1[3JINmdGy\|LDDJR\|UxKD1iND6zJO69VS5?	NUS2NFQxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOFc2PTRpPkG4NlQ4PTV2PD;hQi=>
HL60	NUHTZXBFSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NVzlSmV{PDhiaILz	MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDRwNUOg{txONg>?	M2DxbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{SwOFE{Lz5{OEO0NFQyOzxxYU6=
MDA-MB-231	MmHJRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M1Sxe\|czKGi{cx?=	M3LzWmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHHmeIVzKDd{IHjyd{BjgSCPVGStZoF{\WRiYYPzZZktKEmFNUCgQUA1NjZ\|IN88UU4>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5NEOyOkc,OjV6N{SzNlY9N2F-
K562	MYrGeY5kfGmxbjDhd5NigQ>?			NYXObXdCUW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KHCjcoTpZYxtgSCydYLp[olm\CCqaYP0c45mKGSnYXPleJlt[XOnIH;mJIh2dWGwIHzleYtmdWmjIFu1OlIh[2WubIOuMEBKSzVyIE2gOE45KM7:TT6=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODR{NUGxNEc,OTB2MkWxNVA9N2F-
HeLa	M33D[mZ2dmO2aX;uJIF{e2G7			MYrJcohq[mm2aX;uJI9nKEiGQVOg[pJwdSCqdX3hckBJ\UyjIHPlcIx{KGG\|c3Xzd4VlKGG\|IH;mJIhqe3SxbnWgTFMh[WOndInsZZRqd25uIFnDOVAhRSB2Lkig{txONg>?	NG[wWJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUWzOFU{PCd-MUm1N\|Q2OzR:L3G+
MGC803	M3vMdmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NEHUSoM4OiCqcoO=	M2HCdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVfDPFA{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDR2suQCCjc4PhfUwhUUN3MDC9JFQvQDlizszNMi=>	NEDTN409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUKwNlM6Pyd-MkmyNFI{QTd:L3G+
PC3	NHXoTJlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NFLwW5A1QCCqcoO=	M1HE[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB2Lki5JO69VS5?	Mn\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3MUG5NFYoRjJ6NUGxPVA3RC:jPh?=
HuH7	NHzxXndEgXSxdH;4bYNqfHliYYPzZZk>		MV6zJIRigXN?	M3q4TmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGh2UDdiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuII\pZYJqdGm2eTDh[pRmeiB\|IHThfZMh[nliQ3XscHRqfGW{IEm2JIF{e2G7LDDDR\|UxKD1iNT6xJO69VS5?	M{iwWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEmwO\|AxLz5{NUS5NFcxODxxYU6=
HCT116	M{XvO2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NViwRok6PzJiaILz	MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFUvOSEQvF2u	Mn3HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzNEC5OlEoRjJ4MUSwPVYyRC:jPh?=
A549	MW\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NUHYZ\|NZPzJiaILz	Mo\zRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigZYZ1\XJiN{KgbJJ{KGK7IF3UWE1j[XOnZDDhd5NigSxiSVO1NEA:KDVwNEGg{txONg>?	NIflNXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3OFMzPid-MkW4O\|Q{OjZ:L3G+
A549	MWDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NF3vOXk4OiCqcoO=	NHPkcFFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgbY5kfWKjdHXkJIZweiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNT60NUDPxE1w	Ml[5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NUO3NlIoRjJ3OUWzO\|IzRC:jPh?=
A2780	M2XibWFvfGmlYX7j[ZIh[XO\|YYm=		MoXjO\|IhcHK\|	NVTJe3RuSW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJGEzPzhyIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEeLIE2gOU44KM7:TT6=	MmLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5NEG4N\|QoRjJzN{SxPFM1RC:jPh?=
A549	NVf3ZmtNT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlS2OFghcHK\|	M4fOXmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgOFghcHK\|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFfJOVAhRSB3Lke2JO69VS5?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN7NUG1NEc,Ojh\|OUWxOVA9N2F-
A2780	NWftfXZzSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MkHrOFghcHK\|	M3TRU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUK3PFAh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEWuPFkh\|ryPLh?=	NEfGZWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO0NFQyOyd-MkizOFA1OTN:L3G+
SMMC7721	NYn5NphvSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NIj2R2c4OiCqcoO=	NEjSOFFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPNUWM4PzJzIHPlcIx{KGGodHXyJFczKGi{czDifUBES0tvODDhd5NigSxiSVO1NEA:KDVwOUeg{txONg>?	MkLjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{MEKzPVcoRjJ7MkCyN\|k4RC:jPh?=
U266	M2nM[GFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MmLUOFghcHK\|	M4nqeGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUK2OkBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNj6xJO69VS5?	NHe2dXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESxOVAxQSd-Mki0NVUxODl:L3G+
PC3	NWD2WHR5SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MWm0PEBpenN?	MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hPi5\|NjFOwG0v	M3\2OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{SwOFE{Lz5{OEO0NFQyOzxxYU6=
U251	NVzEbm56T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NEjMTZgzKGSjeYO=	NGLjeo5Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBWOjVzIHPlcIx{KGGodHXyJFIh\GG7czDifUBOXFRiYYPzZZktKEeLNUCgQUA3NjVizszNMi=>	M1jQ[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUSxN\|k1Lz5{MkW0NVM6PDxxYU6=
NCI-H1299	M3nLc2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		M3KyTVczKGi{cx?=	MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3INVI6QSClZXzsd{Bi\nSncjC3NkBpenNiYomgR2NMNThiYYPzZZktKEmFNUCgQUA3Njd2IN88UU4>	NFjXUWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUKwNlM6Pyd-MkmyNFI{QTd:L3G+
AsPC1	MmfjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MUW0PEBpenN?	MnfWS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gRZNRSzFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFfJOVAhRSB4Lkmg{txONg>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN7NUG1NEc,Ojh\|OUWxOVA9N2F-
BGC823	NU\yXpZMT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{XRfVczKGi{cx?=	NEfMbZdIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBDT0N6MkOgZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhX1OWIHT5[UBz\WS3Y4Tpc44h[XO\|YYmsJGdKQTBiPTC3MlEh\|ryPLh?=	MkL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkGzO\|YoRjJ\|ME[xN\|c3RC:jPh?=
MCF7	NWnKTYJTS3m2b4TvfIlkcXS7IHHzd4F6		NEP1UYU4OiCqcoO=	NILRVFdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUA4Njh6MTFOwG0v	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF2MEm2NUc,OjZzNEC5OlE9N2F-
DU145	NFG0WJJCdnSrY3HuZ4VzKGG\|c3H5		MmfHO\|IhcHK\|	NU\WZYV2SW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEeLIE2gO{46KM7:TT6=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd2MUizOEc,OjF5NEG4N\|Q9N2F-
Bel7402	NXTqdXBJT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHfzfpE4OiCqcoO=	NEfwRWFIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBD\Wx5NECyJINmdGy\|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KFeVVDDkfYUhemWmdXP0bY9vKGG\|c3H5MEBIUTlyIE2gPEDPxE1w	MljjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkGzO\|YoRjJ\|ME[xN\|c3RC:jPh?=
HeLa	M4PlXGZ2dmO2aX;uJIF{e2G7		MmXKNlAhdWmwcx?=	MWLJcohq[mm2aX;uJI9nKEiGQVOgbY4hcHWvYX6gTIVN[SClZXzsd{B2e2mwZzDmcJVweiCmZTDMfZMh[XNic4Xid5Rz[XSnIHnuZ5Vj[XSnZDDmc5IhOjBibXnud{BjgSCvaXPyc5Bt[XSnIIPw[YN1em:obIXvdo9u\XS{aXOgZY5idHm\|aYOsJGlEPTBiPTC4MlAzKM7:TT6=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB4MEe2OEc,OjdyNkC3OlQ9N2F-
MGC803	M2\nR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGC1Umw4OiCqcoO=	NGDPSZpIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOT0N6MEOgZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhX1OWIHT5[UBz\WS3Y4Tpc44h[XO\|YYmsJGdKQTBiPTC4Mlkh\|ryPLh?=	M1T3[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[xN\|c3Lz5{M{C2NVM4PjxxYU6=
K562	NHvXcnJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M2HqW\|Q5KGi{cx?=	M{[1UWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS{W2NkBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDHTVUxKD1iOT6zNkDPxE1w	NES1cJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[yPVY{OCd-Mki2Nlk3OzB:L3G+
SMMC7721	NHP1fndIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4XqWVczKGi{cx?=	MYTHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTUW1EPzd{MTDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBYW1RiZInlJJJm\HWldHnvckBie3OjeTygS2k6OCB;IEGxJO69VS5?	M{LKblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[xN\|c3Lz5{M{C2NVM4PjxxYU6=
HeLa	NYDkfoNQTnWwY4Tpc44h[XO\|YYm=		Mkn3NlQhfG9iNEigbJJ{	NX7jcWFFUW6qaXLpeIlwdiCxZjDISGFEKGmwIHj1cYFvKEinTHGgZ4VtdHNidYPpcochSm:lLVz5d{hCSylvQV3DJIF{KHO3YoP0doF1\SCjZoTldkAzPCC2bzC0PEBpenNiYomgd5Bm[3S{b3\seY9zd22ndIL5MEBKSzVyIE2gNVEvOThizszNMi=>	NWnvRnlmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5PVY{PzJpPkK2PVk3Ozd{PD;hQi=>
HeLa	NH\NbpVHfW6ldHnvckBie3OjeR?=			MYHJcohq[mm2aX;uJI9nKEiGQVOgbY4hUGWOYTDj[YxteyxiSVO1NEA:KDF{LkW4PVIh\|ryPLh?=	NXPHVYdvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2NFY{PzBpPkG3OlA3OzdyPD;hQi=>
SKHEP1	NUnTRXJWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{LYW\|czKGi{cx?=	M1Ow[mdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNMUEWSMTDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBYW1RiZInlJJJm\HWldHnvckBie3OjeTygS2k6OCB;IEGzJO69VS5?	MofKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkGzO\|YoRjJ\|ME[xN\|c3RC:jPh?=
A549	NXu4XYl7SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NFHSbZc1QCCqcoO=	Ml;MRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSBzOD6zO{DPxE1w	NGrLb\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[yPVY{OCd-Mki2Nlk3OzB:L3G+
PC3	MV;BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M{G1S\|Q5KGi{cx?=	Ml3tRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCSQ{OgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiR1m1NEA:KDF7LkC5JO69VS5?	NF7DbXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[yPVY{OCd-Mki2Nlk3OzB:L3G+
HeLa	NF[zclVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MWO0PEBpenN?	M1:2V2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXMZUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDHTVUxKD1iMUmuNlQh\|ryPLh?=	M1i2TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkK5OlMxLz5{OE[yPVY{ODxxYU6=
MCF7	NIjZXJlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		Mkn1OFghcHK\|	NFjNSXVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IEG5MlI3KM7:TT6=	NIO5UFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[yPVY{OCd-Mki2Nlk3OzB:L3G+
HCT116	NHOzOYFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		Mo\sOFghcHK\|	Mo\PRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEK3MlQ4KM7:TT6=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDdyMUOwNUc,OTh5MEGzNFE9N2F-
U251	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MV:yJIRigXN?	MmW5S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gWVI2OSClZXzsd{Bi\nSncjCyJIRigXNiYomgUXRVKGG\|c3H5MEBVT0liPTC0NEDPxE1w	NWHoXG96RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFE{QTRpPkKyOVQyOzl2PD;hQi=>
HEK293 STF	MXXGeY5kfGmxbjDhd5NigQ>?		NGjrNnczPCCqcoO=	M37lNWFkfGm4YYTpc44hd2ZibX;1d4UhX262M3Ggd4lodmGuaX7nJIV5eHKnc4Pl[EBqdiCKRVuyPVMhW1SIIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJRz[W6\|Y4LpdJRqd26jbDDhZ5Rqfmm2eTDh[pRmeiB{NDDodpMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mNWKjc3XkJIxi[3SjdHWg[IVpgWS{b3flcoF{\SCjc4PhfU4>	M1nvRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEKyOlc2Lz5zOUCyNlY4PTxxYU6=
U937	MX3GeY5kfGmxbjDhd5NigQ>?	NFnXNnU2KHWP	NYXVO4l1OjRiaILz	NI\5[HpKdmO{ZXHz[UBqdiCqaYP0c45mKEh\|IHHj[ZR6dGG2aX;uJIlvKFV7M{egZ4VtdHNiYYSgOUB2VSCjZoTldkAzPCCqcoOgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|Lh?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR2N{e1NEc,OTd2NEe3OVA9N2F-
U937	NXu2eFBtTnWwY4Tpc44h[XO\|YYm=			MkTzTY5pcWKrdHnvckBw\iCqdX3hckBJTEGFMTDpckBWQTN5IHPlcIx{KGK7IHntcZVvd3C{ZXPpdIl1[XSrb36gZZN{[Xlw	NV:zZnJyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizPFEzOzhpPkG4N\|gyOjN6PD;hQi=>
U937	NUjRUnl1TnWwY4Tpc44h[XO\|YYm=			NUTUW\|IxUW6mdXP0bY9vKG:oIHjpd5RwdmViSESgbJlx\XKjY3X0fYxifGmxbjDpckBpfW2jbjDVPVM4KGOnbHzzMi=>	M3v4cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{ixNlM5Lz5zOEO4NVI{QDxxYU6=
U937	NHKxTIpHfW6ldHnvckBie3OjeR?=			NVzwUnFxUW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDOEBqdiCXOUO3JINmdGy\|IHL5JIludXWwb4Dy[YNqeGm2YYTpc44h[XO\|YYmu	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN6MUKzPEc,OTh\|OEGyN\|g9N2F-
U937	MojLSpVv[3Srb36gZZN{[Xl?			NUXXcm9CUW6mdXP0bY9vKG:oIHfyZY52dG:leYTpZ{BlcW[oZYLlcpRq[XSrb36gbY4hcHWvYX6gWVk{PyClZXzsd{4>	NIrqUVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO4NVI{QCd-MUizPFEzOzh:L3G+
HCT116	NXvjXZBvTnWwY4Tpc44h[XO\|YYm=	MXKxNEB2VQ>?	NV;MWHVKOjRiaILz	NITOOoVKdmirYnn0bY9vKG:oIFjERWMyKGmwIHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{BqdmS3Y4Tpc44hd2ZiaInw[ZJi[2W2eXzheIlwdiCxZjDobZN1d26nIFizJIF1KDFyIIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZMv	M331UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEWyNlI3Lz5{MES1NlIzPjxxYU6=
NB4	NHnV[I5E\WyuIHP5Z4xmKGG{cnXzeEBie3OjeR?=	NHnjb202KHWP	MU[yOEBpenN?	NInvOVBE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBPSjRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gZYNkfW23bHH0bY9vKGG2IIDy[U1IOSCyaHHz[UBifCB3IIXNJIFnfGW{IEK0JIhzeyCkeTDGRWNUKGGwYXz5d4l{Ng>?	M17HdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEmxOFQxLz5{MES5NVQ1ODxxYU6=
NB4	NUKwdXk{TnWwY4Tpc44h[XO\|YYm=	NF3sVmQ2KHWP	M3TBUlI1KGi{cx?=	NI\YSFdKdmS3Y4Tpc44hd2ZicEKxW2FHOS:FSWCxJIV5eHKnc4Ppc44hcW5iaIXtZY4hVkJ2IHPlcIx{KGG2IEWgeW0h[W[2ZYKgNlQhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqey5?	NVvkW\|l4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0PVE1PDBpPkKwOFkyPDRyPD;hQi=>
epithelial cells	NV:1bnVRTnWwY4Tpc44h[XO\|YYm=	M3\1UVEhfU1?	Ml\hOEwhPixiYX7kJFgh\GG7cx?=	MojMTY5pcWKrdHnvckBw\iCKRFHDO{BqdiCqdX3hckBpd22xeonnc5V{KE[mZXz0ZVUxQCCycnntZZJ6KGK{b37jbIlidCCncHn0bIVtcWGuIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJNpd3K2IHPpdoN2cXRiY4XydoVvfHNiYYSgNUB2VSCob4KgOEwhPixiYX7kJFgh\GG7czDy[YxifGm4ZTD0c{Bkd262cn;sMi=>	NE\QOlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm2Olc5QSd-MUm5OlY4QDl:L3G+
Hela	M3\WWmZ2dmO2aX;uJIF{e2G7	NYDqeYN2OC54IIXN	MWOxOkBpenN?	MkDwTY5pcWKrdHnvckBw\iCKRFHDOkBqdiCqdX3hckBJ\WyjIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJRwfGGuIHz5d4lv\SCjY3X0fYxifGmxbjDheEAxNjZidV2gZYZ1\XJiMU[gbJJ{KGK7IHntcZVvd2[udX;y[ZNk\W6lZTDtbYNzd3Olb4D5Mi=>	NIWwVFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MU[5Olk2Pid-MkG2PVY6PTZ:L3G+
U937	M1XDV2NmdGxiY4njcIUh[XK{ZYP0JIF{e2G7	NX:0PJlsPSC3TR?=	NFPtcnI{OCCqcoO=	NWPjVWo2S2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hXTl\|NzDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{GgdIhie2ViYYSgOUB2VSCjZoTldkA{OCCqcoOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{Bj[XOnZDDmcI94KGO7dH;t[ZRzgS5?	NFfiTHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKxOVY1Pyd-MkGyNVU3PDd:L3G+
epithelial cells	NYTxTY9JTnWwY4Tpc44h[XO\|YYm=	M33DR\|UhfU1?		NUXHcnR5UW6qaXLpeIlwdiCxZjDISGFEKGmwIHj1cYFvKHC{aX3hdpkh[nKxbnPobYFtKGWyaYTo[Yxq[WxiY3XscJMh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJI12fGGwdDDG[IVtfGF3MEigR2ZVWiCycn;0[YlvKGGyaXPhcEB{fXKoYXPlJIxw[2GuaYrheIlwdiCjdDC1JJVONg>?	MkPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7Nk[3PFkoRjF7OU[2O\|g6RC:jPh?=
NB4	M3XC[GZ2dmO2aX;uJIF{e2G7	NF7yTHg2KHWP	MorNNlQhcHK\|	NUPyfpVMUW6qaXLpeIlwdiCxZjDISGFEKGmwIHj1cYFvKE6ENDDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg{KGGlZYT5cIF1cW:wIHH0JFUhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcz6=	M1;kPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEmxOFQxLz5{MES5NVQ1ODxxYU6=
C127-LT	M1\Z[mZ2dmO2aX;uJIF{e2G7	NIrSU\|EyKHWP	M3P2T\|I1KGi{cx?=	M1;od2lvcGmkaYTpc44hd2ZiSFTBR{BqdiCvb4Xz[UBEOTJ5LVzUJINmdGy\|IHHzd4V{e2WmIHHzJIFkfGm4YYTpc44hd2ZiRVfGVEBmgHC{ZYPzbY9vKGG2IEGgeW0h[W[2ZYKgNlQhcHK\|IHL5JIZtfW:{ZYPj[Y5k\SCvaXPyc5Nkd3C7Lh?=	NWjuenlSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5PVY{PzJpPkK2PVk3Ozd{PD;hQi=>
C127-LT	MVLGeY5kfGmxbjDhd5NigQ>?	M3jSflExKHWP	M1i1OFI1KGi{cx?=	NX7SXlNOUW6qaXLpeIlwdiCxZjDISGFEKGmwIH3veZNmKENzMketUHQh[2WubIOgZZN{\XO\|ZXSgZZMh[WO2aY\heIlwdiCxZjDFS2ZRKGW6cILld5Nqd25iYYSgNVAhfU1iYX\0[ZIhOjRiaILzJIJ6KG[udX;y[ZNk\W6lZTDtbYNzd3Olb4D5Mi=>	NF7xVZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm5OlM4Oid-Mk[5PVY{PzJ:L3G+
HCT116	MlX4SpVv[3Srb36gZZN{[Xl?	MlzSNVAhfU1?	MWWyOEBpenN?	NFnjZ4dKdmirYnn0bY9vKG:oIFjERWMzKGmwIHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{BpgXCncnHj[ZR6dGG2aX;uJI9nKGirc4TvcoUhUDNiYYSgNVAhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcz6=	NWPkTFZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNlEzOTVpPkKyN\|IyOjF3PD;hQi=>
HCT116	MXTGeY5kfGmxbjDhd5NigQ>?	NXLLToF1OTBidV2=	NXrBNJdVOjRiaILz	NXPScJpCUW6qaXLpeIlwdiCxZjDISGFEOSCrbjDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO\|ZXSgZZMhcHmyZYLhZ4V1gWyjdHnvckBw\iCqaYP0c45mKEh\|IHH0JFExKHWPIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYOu	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN{MUKxOUc,OjJ\|MkGyNVU9N2F-
TC32	MYPxTHRUKGG\|c3H5			NIPXZYpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucz6=	Ml3QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
U-2 OS	NWnuOJQ6eUiWUzDhd5NigQ>?			MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|Lh?=	NIDxWZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	NUHSU4VLeUiWUzDhd5NigQ>?			MVvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtey5?	NFHHPFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	MlrRdWhVWyCjc4PhfS=>			NIDuWIxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucz6=	NHfZXlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Saos-2	M2D4WpFJXFNiYYPzZZk>			M3zFOJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIOu	MnnHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	NH60[ZJyUFSVIHHzd4F6			MVrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHNw	NHvQWo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	NXjF[FdUeUiWUzDhd5NigQ>?			MoTZdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{Ng>?	NFzTZ409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	Ml;NdWhVWyCjc4PhfS=>			MlrZdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIOu	M3nCcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	MnfqdWhVWyCjc4PhfS=>			MmDLdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy\|Lh?=	NVSxZoQ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	NVHUfIdueUiWUzDhd5NigQ>?			NInRZmxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIOu	M3\1TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	M1PzSJFJXFNiYYPzZZk>			MmD3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucz6=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	MXzxTHRUKGG\|c3H5			NVrUZ41[eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsd{4>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
fibroblast cells	NVTZe3E1eUiWUzDhd5NigQ>?			NF;UT5NyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiY3;ueJJwdCCKaDD3bYxlKHS7cHWg[oljem:kbHHzeEBk\Wyucz6=	M1n6dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	MWjxTHRUKGG\|c3H5			NWfhN3VueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHNw	Ml\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
DAOY	NVj3W25OeUiWUzDhd5NigQ>?			MnTsdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgSGFQYSClZXzsd{4>	NH25bFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	MYTxTHRUKGG\|c3H5			M1XubpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy\|Lh?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	NGXrd\|FyUFSVIHHzd4F6			NEnQVZpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBPSi2HQnOxJINmdGy\|Lh?=	NXzEdnFTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30	NFztT3ByUFSVIHHzd4F6			M1KzZ5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEOwJINmdGy\|Lh?=	NUDLS5pCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	M{X3dJFJXFNiYYPzZZk>			NH:5VINyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd\|IHPlcIx{MS5?	NVn2S49tRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	M3HSWJFJXFNiYYPzZZk>			NH3YNo9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBDXC1\|NzDj[Yxtey5?	NYjxc4VLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	Ml;JdWhVWyCjc4PhfS=>			NHSwS2JyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtey5?	M3zyN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30	MXjxTHRUKGG\|c3H5			NWDrNGpbeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh\|MDDj[Yxtey5?	M4\qTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS	NVLlO45OeUiWUzDhd5NigQ>?			M1HidpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHUuOiCRUzDj[Yxtey5?	M1XT[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	MmnIdWhVWyCjc4PhfS=>			M3nafJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG9JWy13MDDj[Yxtey5?	NVrsOHA1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	NVjIfY0zeUiWUzDhd5NigQ>?			M3nlRZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpPDFiY3XscJMv	M3LmTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	NVTKZY1LeUiWUzDhd5NigQ>?			M3PJ[ZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJFKGOnbHzzMi=>	NGLaWXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	NYjOWYpDeUiWUzDhd5NigQ>?			MUHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucz6=	NX;CcnhWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	NXnReVlFeUiWUzDhd5NigQ>?			NFuzfIFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsd{4>	M{j5VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	NV7mdHJSeUiWUzDhd5NigQ>?			M1n1[ZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzzMi=>	M2mxVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	MU\xTHRUKGG\|c3H5			NFnFVYNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIOu	NXfSR4luRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	Mm[0dWhVWyCjc4PhfS=>			MXXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtey5?	M3H5NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	MnLIdWhVWyCjc4PhfS=>			M2XxUZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG5DOTZ2MzDj[Yxtey5?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	NGDybohyUFSVIHHzd4F6			NFHjUHJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLV3DJINmdGy\|Lh?=	Mnr2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	NUXndmxFeUiWUzDhd5NigQ>?			MVXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTTk1ISk1{IHPlcIx{Ng>?	NWXhSGVWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32	NHfrT4RyUFSVIHHzd4F6			MYnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDUR\|MzKGOnbHzzMi=>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	MlyxdWhVWyCjc4PhfS=>			NIPYO\|ZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDF6IHPlcIx{Ng>?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	M4jxeJFJXFNiYYPzZZk>			NXq5dZRyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|Lh?=	NVq4ZphQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
HeLa	NIqyO29HfW6ldHnvckBie3OjeR?=	NYD2U4ZQOSC3TR?=	MoLCOkBpenN?	MVTJcohq[mm2aX;uJI9nKEiGQVOxM2hFSUN{L1jERWM{KGmwIHj1cYFvKEinTHGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcW62cnHj[YxtfWyjcjDhZ4V1gWxvaHnzeI9v\SCKNDDs[ZZmdHNiYYSgNUB2VSCjZoTldkA3KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXNw	MmSyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5OEeyOlIoRjJ7N{i3NlYzRC:jPh?=
MV4-11	M2H6OWFxd3C2b4Ppd{Bie3OjeR?=	NWfDVIdvPSC3TR?=	MVWyOEB1dyB2ODDodpM>	NFKxZo9KdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF3WOE0yOSClZXzsd{BifCB3IIXNJIFnfGW{IEK0JJRwKDR6IHjyd{BjgSCDbn7lfIlvKFZvUFmgd5RicW6rbnegZoF{\WRiZnzve{BkgXSxbXX0dpkv	NXjJZ4FZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3N\|g6PTNpPkK5O\|M5QTV\|PD;hQi=>
MV4-11	MW\GeY5kfGmxbjDhd5NigQ>?	M3rIV\|IxOCCwTR?=	NWP2XZNJOjRiaILz	M4DidGlvcGmkaYTpc44hd2ZiY3zhd5MhOSCKRFHDJIlvKGi3bXHuJG1XPC1zMTDj[YxteyCjc4Pld5Nm\CCjczDofZBmemGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFMh[XRiMkCwJI5OKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXNw	NWjIS5l{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3N\|g6PTNpPkK5O\|M5QTV\|PD;hQi=>
HL60	M2iyTmFxd3C2b4Ppd{Bie3OjeR?=	M3vXTFUhfU1?	NYXZbng3PDhiaILz	MnW1TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKTE[wJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKHC{b3Phd5Bie2VvMzDs[ZZmdCCjdDC1JJVOKGGodHXyJFQ5KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXNw	NFLGOpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESxOVAxQSd-Mki0NVUxODl:L3G+
HL60	NULWRZhbSXCxcITvd4l{KGG\|c3H5	M2i0blUhfU1?	M3TucVQ5KGi{cx?=	MUDJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiONkCgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4h[2ynYY\l[EBk[XOyYYPlMVMhdGW4ZXygZZQhPSC3TTDh[pRmeiB2ODDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nzMi=>	NYjINJVORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NVUxODlpPkK4OFE2ODB7PD;hQi=>
HL60	MnqwRZBweHSxc3nzJIF{e2G7	M33JZVUhfU1?	M3PJPVQ5KGi{cx?=	Mn;6TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKTE[wJINmdGy\|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGOuZXH2[YQhWEGUUDDs[ZZmdCCjdDC1JJVOKGGodHXyJFQ5KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXNw	M1TPOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEG1NFA6Lz5{OESxOVAxQTxxYU6=
MV4-11	NHn6O4JE\WyuIHP5Z4xmKGG{cnXzeEBie3OjeR?=	MWC1JJVO	NHTxfIkzPCCqcoO=	NYrab4RyS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hVVZ2LUGxJINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDzeYIuTzFicHjhd4Uh[XRiNTD1UUBi\nSncjCyOEBpenNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobH;3JIN6fG:vZYTybYMhdWW2aH;kMi=>	NFvCbGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW4PVQ1OSd-Mkm1PFk1PDF:L3G+
HEL	NFW3[IFE\WyuIHP5Z4xmKGG{cnXzeEBie3OjeR?=	MVS1JJVO	M4fhN\|I1KGi{cx?=	MYfD[YxtKGO7Y3zlJIFzemW\|dDDpckBpfW2jbjDISWwh[2WubIOgZZQhPSC3TTDh[pRmeiB{NDDodpMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndG:5IHP5eI9u\XS{aXOgcYV1cG:mLh?=	MmLJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3OEm0OFEoRjJ7NUi5OFQyRC:jPh?=
Jurkat	NF76dpBE\WyuIHP5Z4xmKGG{cnXzeEBie3OjeR?=	MYK1JJVO	MWSyOEBpenN?	NXOzVVBPS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hUnW{a3H0JINmdGy\|IHH0JFUhfU1iYX\0[ZIhOjRiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[oxwfyCleYTvcYV1emmlIH3leIhw\C5?	M4jBT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUi5OFQyLz5{OUW4PVQ1OTxxYU6=
MV4-11	NF\BPXhHfW6ldHnvckBie3OjeR?=	MYi1JJVO	M4O3ZVI1KGi{cx?=	NIfabo5KdmirYnn0bY9vKG:oIHPsZZN{KDFiSFTBR{BqdiCqdX3hckBOXjRvMUGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKGirc4TvcoUhcHmyZYLhZ4V1gWyjdHnvckBifCB3IIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5QhdWW2aH;kMi=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV6OUS0NUc,Ojl3OEm0OFE9N2F-
LNCAP	NUXnbJJJTnWwY4Tpc44h[XO\|YYm=	NYr2bG5mOTBidV2=	M1zxO\|I1KGi{cx?=	Mk\STY5pcWKrdHnvckBw\iCKRFHDOkBqdiCqdX3hckBNVkODUDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKESKVD3pcoR2[2WmIHHsdIhiNXS3YoXsbY4h\GWjY3X0fYxifGmxbjDifUBu\WG\|dYLpcochcW6lcnXhd4UhcW5iYXzwbIEufHWkdXzpckBi[2W2eXzheIlwdiCjdDCxNEB2VSCvZXHzeZJm\CCjZoTldkAzPCCqcoOgdoVt[XSrdnWgeI8h[2:wdILvcE4>	Mn3uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5MUe1OFQoRjJ5N{G3OVQ1RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; PubMed: 24203492 Pharm Res HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. Cleaved PARP; PubMed: 19148581 J Neurooncol Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control. Caspase 8 ; PubMed: 19148581 J Neurooncol Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression. DR4 / DR5; PubMed: 19148581 J Neurooncol Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h. TopoIIα / TopoIIβ; PubMed: 21254166 Hepatology Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.	24203492 19148581 21254166
Immunofluorescence	phalloidin / snail; PubMed: 29855565 Sci Rep (C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed. DR4 / DR5; PubMed: 19148581 J Neurooncol Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls. H3K4Me3 / H3K9Me3; PubMed: 22468166 Mol Cell Pharmacol Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.	29855565 19148581 22468166
Growth inhibition assay	Cell proliferation; PubMed: 24203492 Pharm Res (A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. , P < 0.05, ; P ≤ 0.01; **, P ≤ 0.001 Cell viability; PubMed: 28969017 Oncotarget PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.	24203492 28969017
ELISA	GCP-2 / MCP-2 / MIF ; PubMed: 24241152 Molecules MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).	24241152

In vivo

MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. ^[1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. ^[4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. ^[5]

Protocol

Kinase Assay: ^[6]	- Collapse Standard HDAC Assays: Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λ_ex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. K_m and V_max values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research: ^[2]	- Collapse Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells Concentrations: ~ 10 μM Incubation Time: 3 days Method: Cancer cells (5 × 10³) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO₂-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na₂HPO₄ is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice. Dosages: 12.3, 24.5 and 49 mg/kg Administration: Administered orally once daily 5 days per week for 4 weeks (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	75 mg/mL (199.25 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Entinostat (MS-275) SDF

Molecular Weight	376.41
Formula	C₂₁H₂₀N₄O₃
CAS No.	209783-80-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	SNDX-275
Smiles	C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04708470	Not yet recruiting	Drug: Bintrafusp Alfa\|Drug: NHS-IL12\|Drug: Entinostat	Cancer\|Solid Tumor\|Metastatic Checkpoint Refractory HPV Associated Malignancies\|Microsatellite Stable Colon Cancer (MSS)	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	May 18 2021	Phase 1\|Phase 2
NCT03829930	Recruiting	Drug: Entinostat\|Drug: Enzalutamide	Prostate Adenocarcinoma	George Washington University	May 1 2019	Phase 1
NCT03765229	Recruiting	Drug: Entinostat\|Drug: Pembrolizumab	Melanoma	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals Inc.	March 22 2019	Phase 2
NCT03473639	Recruiting	Drug: Entinostat\|Drug: Capecitabine	Metastatic Breast Cancer\|Breast Cancer	University of Virginia\|Syndax Pharmaceuticals	January 29 2019	Phase 1
NCT03361800	Terminated	Drug: Entinostat	Breast Cancer\|Invasive Breast Cancer\|ER-Negative PR-Negative HER2-Negative Breast Cancer	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals\|National Cancer Institute (NCI)	November 28 2018	Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to use Entinostat（Catalog No.S1053） for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?
Answer:
2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

CAY10603 ^New

CAY10603 (BML-281) is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

Domatinostat (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Entinostat (MS-275)